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Abstract: Nonalcoholic fatty liver disease (NAFLD) represents a global healthcare burden since it is
epidemiologically related to obesity, type 2 diabetes (T2D) and Metabolic Syndrome (MetS). It embraces
a wide spectrum of hepatic injuries, which include simple steatosis, nonalcoholic steatohepatitis
(NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The susceptibility to develop NAFLD
is highly variable and it is influenced by several cues including environmental (i.e., dietary habits
and physical activity) and inherited (i.e., genetic/epigenetic) risk factors. Nonetheless, even intestinal
microbiota and its by-products play a crucial role in NAFLD pathophysiology. The interaction of
dietary exposure with the genome is referred to as ‘nutritional genomics,’ which encompasses both
‘nutrigenetics’ and ‘nutriepigenomics.’ It is focused on revealing the biological mechanisms that entail
both the acute and persistent genome-nutrient interactions that influence health and it may represent
a promising field of study to improve both clinical and health nutrition practices. Thus, the premise
of this review is to discuss the relevance of personalized nutritional advices as a novel therapeutic
approach in NAFLD tailored management.
Keywords: nonalcoholic fatty liver disease; nutrigenomics; nutrigenetics; nutriepigenomics;
gene-diet interaction
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is now considered the most frequent cause of liver
disorders worldwide, affecting more than one third of the general population [1]. Since it has been
reaching global epidemic proportions, it represents one of the major social, economic and public health
issues in western countries [1]. NAFLD is defined by hepatic fat accumulation that exceeds 5% of
liver weight, in absence of alcohol abuse, and it entails a broad spectrum of conditions, spanning from
simple and uncomplicated steatosis to nonalcoholic steatohepatitis (NASH), which is characterized
by hepatocyte ballooning, lobular inflammation and fibrosis that could worsen into cirrhosis and
hepatocellular carcinoma (HCC) [2,3].
NAFLD is epidemiologically associated with obesity, type 2 diabetes (T2D), and metabolic
syndrome (MetS) features [4] and its pathogenesis is closely entangled with increased adiposity, insulin
resistance (IR) and dyslipidemia [5]. Indeed, dietary habits such as excessive caloric intake, high
fructose consumption and poor physical activity represent paramount risk factors for this condition [6].
Furthermore, the inter-individual susceptibility to develop NAFLD may be partially explained by
inherited factors [7]. Single nucleotide polymorphisms (SNPs) in genes regulating hepatic lipid handling,
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including Patatin-like Phospholipase Domain-containing 3 (PNPLA3), Transmembrane 6 Superfamily Member
2 (TM6SF2) and Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7), have been associated
with NAFLD predisposition and progression towards NASH and fibrosis [7]. However, less than 10%
of inherited variability is explained by these common variants. In particular, many of the phenotypic
discrepancies may also result from complex gene-environment interactions, explained by epigenetic
mechanisms, hereditable but reversible modifications that modulate the transcriptome in response to
environmental cues, without altering DNA sequence [8]. Epigenetics encompasses a wide number of
events such as alterations of DNA nucleotides (i.e., methylation of CpG dinucleotides, known as CpG
islands), modifications of histones and regulation of transcription by altering mRNA stability through
small RNA molecules such as microRNAs (miRNAs). Therefore, it may provide a new perspective in
NAFLD pathogenesis, diagnosis and management [9]. Nonetheless, among the plethora of multiple
parallel hits, recent evidence has pointed out the role of intestinal dysbiosis, microbial metabolites and
enhanced intestinal permeability in the pathophysiology of fatty liver [10,11].
Currently, no therapeutic consensus exists for the treatment of NAFLD patients, and lifestyle
intervention with a focus on healthy eating and regular physical exercise and weight loss remain
the mainstay in the management of patients with NAFLD. Indeed, effective and sustained weight
loss has been associated with marked improvement in glycemic control, hepatic insulin sensitivity,
liver enzymes and liver histology [6]. However, it has been demonstrate that each individual differs
in response to diet, according to the genetic background [6]. The interaction between nutritional
environment and inherited factors is being referred to as ‘nutritional genomics’ or ‘nutrigenomics,’
which encompasses both ‘nutrigenetics’ and ‘nutriepigenomics’ [12,13]. Nutritional genomics may
represent a promising field of study to improve both clinical and health nutrition practices, establishing
genome-based dietary guidelines for disease prevention, individualized nutrition therapy for disease
management and targeted public health nutrition interventions [13]. It is focused on revealing the
biological mechanisms that entail both the acute and persistent genome-nutrient interactions that
influence health [13].
For this reason, this review aimed to address to the relevance of personalized nutritional approaches
in the tailored NAFLD clinical management and its pivotal role as therapeutic strategy to ameliorate
liver damage and to avoid its progression towards end-stage conditions. Moreover, the discovery of
possible nutrigenomic approaches may contribute to explain how dietary habits differently impact on
health depending on the individual’s genetic makeup.
2. Methodological Approaches to Nutritional Genomics
In the last decades, the prevalence of metabolic disorders (e.g., NAFLD, obesity and T2D) has
exponentially increased in Western countries. This escalation is strictly correlated with changes
in dietary habits. Indeed, the Western diet is evolutionally modified, replacing fruits, vegetables,
proteins and omega-3 fatty acids with saturated and trans-fat, omega-6 fatty acids, carbohydrates and
high-energy nutrients [14]. It has been demonstrated that nutritional and lifestyle interventions exert
beneficial effects on NAFLD outcomes and its comorbidities. Nutritional genomics studies the impact
of nutrients on gene expression, genome evolution and selection, genome mutation rate, and genome
reprogramming [13]. It entails even the detrimental effect exerted by specific macro and micronutrients
on DNA metabolism, addressing mainly their role in DNA synthesis, degradation, repair and alteration.
In turn, the genomic evolution and selection may contribute to the genetic variations observed within
genetically different ethnicities. The deep-knowledge of diet-genome interactions will allow to apply
new approaches on prevention and treatment of chronic disorders by using precision nutrition, which
might be included in the personalized medicine therapy. However, the amount of studies is scarce and
nutrigenomic research remains largely inconclusive. Therefore, there is an urgent need to increase the
number of experimental data in order to unravel these mechanisms and to discover novel appealing
candidate biomarkers for diagnosis as well as to introduce nutraceutical products as preventive or
therapeutic strategy [13]. This paragraph aims to describe the current strategies in this scenario,
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and to elucidate appropriate methodological approaches to nutrigenomics, thus providing the finest
interpretation of the nutritional effect on health outcomes and nutritional guidelines. Three main study
approaches of nutrigenomics will be covered: (1) the effects of nutrients on DNA metabolism; (2) the
study of genetic variability response towards nutrition named nutrigenetics; (3) the effect of nutrients
on genetic expression.
An important aspect of nutrigenomics is the effectiveness of nutrients (especially micronutrients)
on DNA metabolism, even though it is not deeply investigated. Some evidence supports the notion
that several micronutrients are required to maintain DNA homeostasis, as they are cofactors of a
variety of enzymes involved in DNA synthesis and repair [15]. Thus, nutritional deficiency of these
essential micronutrients could induce a strong DNA modification comparable to that observed after
DNA exposure to mutagenic substances or radiations [16]. Fenech et al. tested the association
between dietary micronutrient intake and genome stability in a human trial, using cytokinesis-block
micronucleus assay (CBMN) in lymphocytes. This test is based on the concept that the formation of
micronuclei during cytokinesis, instead of two whole nuclei, is an indicator of DNA damage. These
authors demonstrated that a higher intake of several micronutrients (i.e., calcium, folate, nicotinic acid,
vitamin E, retinol, β-carotene) is associated with a decrease in micronuclei formation, and therefore,
reduced genome damage [17]. This is a highly innovative and reliable method to study genome
alterations in human samples in a simple and non-invasive fashion. The study of micronuclei formation
as a signature of genomic derangement has significant implications for tumorigenesis and cancer
research [16]. Another method to investigate genomic stress is the assessment of telomere length.
Indeed, telomeres shortening is a hallmark of aging and of several chronic diseases, among which
NAFLD [18]. A broad number of studies demonstrated that dietary habits have either protective
or noxious effects on telomere length. For instance, high consumption of vegetables and omega-3
fatty acids were associated with longer telomeres, whereas higher intake of saturated fatty acids was
correlated with shorter ones [19]. Therefore, since nutritional pattern is highly relevant in NAFLD
pathogenesis, it can be hypothesized that telomere shortening, and hence genome stress, in NAFLD
patients may be affected by dietary habits.
Another area of interest of nutrigenomics is represented by nutrigenetics. The latter entails the
study of the effect of a genotype (e.g., the presence of SNPs or other genetic variations) towards
specific dietary patterns. Indeed, each subject could respond differently to nutritive substances, and
genetic variations within different human populations are a consequence of the adaptive evolution to
specific dietary habits. Common SNPs in DNA sequence constitute the primary example of genetic
variation. They arise from a process of DNA mutation and subsequent selection in the populations.
Nutritional environment intervenes in this evolutionary process, precipitating the expansion of DNA
mutations within the subjects. For instance, Vitamin B deficiency as well as high iron intake strongly
impair DNA synthesis and stability, enhancing the rate of germ line and somatic mutations. Likewise,
derangements in folate metabolism enhance the risk of several diseases such as cancers, cardiovascular
disorders and neurological disorders [20]. Genetic variants that alter folate-dependent enzymes
can confer an increased or decreased susceptibility to develop these abnormalities. Indeed, the
common SNP in the Methylenetetrahydrofolate Reductase (MTHFR) gene, 677C>T enhances the risk
for neural tube anomalies [21] and metabolic disorders such as NAFLD [22]. However, the same
polymorphism has been also demonstrated to be protective against colon cancer in folate-supplemented
individuals [23]. The prevalence of this SNP is highly heterogeneous among the different ethnicities
(the allele frequency is 20% in Hispanics, rare in Africans) as a consequence of the selection due to the
nutritional environment [24]. However, several genetic variants affecting nutrient utilization that are
penetrated in the population through positive selection are to date considered inherited risk factors for
metabolic disorders (i.e., C282Y variant in HFE gene) [25].
Due to the complexity of gene-diet interactions, recent steps forward have been carried out
to promote nutritional research. The study of the effect of genetic variations on dietary intake in
the field of metabolic disorders is possible through genetically edited in vitro models such as cell
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lines, co-cultures and three-dimensional (3D) cultures and the use of mice models (e.g., knock-out,
knock-in) bearing the mutations of interest. In these models, the harmful effects of fatty acids overload
or obesogenic/steatogenic diets, respectively, could be influenced by the genetic background and
potentially be reverted through healthy micro/macronutrients supplementation [26]. In particular, the
breakthrough in the field of genome editing reached the top with the introduction of Clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 for both in vivo and in vitro models, which
offers the advantage to reduce the off-target effects occurring with other techniques. Furthermore,
human-derived organoids from stem cells represents innovative attractive models, capable to
differentiate into multiple cell lineages according to the culture conditions [26].
Nutrigenomic study investigates also the effect of nutrients on gene expression. The primary goals
of this nutrigenomic approach encompass the following steps: (1) to identify the transcription factors
that are sensitive to a specific nutrient and their target genes; (2) to find out which signaling pathways
are activated as a consequence of the targeted genetic transcription, and therefore, possible metabolites
and pathophysiological processes involved; (3) to define cell- and organ-specific response to nutrients
and the relative consequences [27]. These aims are pursued with the implementation of ‘omics’
technologies, among which genomics, transcriptomics, proteomics, metabolomics and system biology.
The latter integrates bioinformatics to “omics” approaches, allowing to identify the functional roles
of different genes in a dynamic network interaction, thus giving rise to the new functional genomics
era [28,29]. Notwithstanding, the application of high-throughput “omics” methods could run into
several limitations: (1) gene expression is often cell/tissue specific, and therefore, a limitation could be
represented by harvesting samples through invasive methods, especially in human studies; (2) analysis
and interpretation of data, which sometimes requires advanced bioinformatic competences [29].
In the past years, DNA microarray technique was the most exploited tool for the analysis of
transcriptomic data and a promising method for nutrigenomic studies, as it may assess the effects of
macro and micronutrients on the entire transcriptome [28]. This information will allow to translate in
detail whether nutrients’ effects on the transcriptome mirror the consequences on proteome and, in turn,
what downstream pathways are activated. A more innovative transcriptomic tool is RNA sequencing
(RNAseq), which is emerging as an alternative to DNA microarray. Indeed, RNAseq experiments
are more informative, as they can cover a larger spectrum of RNAs compared to microarrays, also
detecting very low expressed RNAs [30].
Once it is clear which transcripts are regulated by nutrients, the function of these transcripts
needs to be investigated; namely, which proteins they codify for. Proteomics is the analysis of
protein expression profile, which reflects cellular activity. Proteomics studies exploit a wide variety
of antibodies-based techniques, such as electrophoretic separations and blotting or enzyme-linked
immunosorbent assay (ELISA). However, a more innovative and advance method for proteome
analysis is mass spectrometry (MS), which simultaneously detects all the proteins synthetized [31].
MS is based on the ionization of molecules (e.g., peptides, proteins) that are detected according to
their mass to charge ratio (m/z). In the past years, MS has played a major role in the development
of proteomics because of its sensitivity and specificity for protein identification and characterization.
Moreover, another important advantage of MS is that it allows to analyze all sorts of samples in liquid
and solid form, such as tissue samples. In this case, MS not only can give quantitative but also spatial
information about protein expression [32]. Additionally, MS is a useful state-of-the-art tool to study
the metabolome. Metabolomics, the most novel “omics” approach used in nutrition, studies the whole
metabolism, from the single cell to the entire organism, and it represents the ending result of the
modifications in gene expression. Metabolomics can be trickier than proteomics because metabolites
have different chemical structures, and therefore, no method makes possible to characterize the whole
metabolome at once. Moreover, the ending molecular result of metabolism can be extremely sensitive
to several environmental factors, not only nutrients, which can be misleading. Another important
method used in metabolomics is Nuclear Magnetic Resonance (NMR) spectroscopy, which enables not
only the quantification of metabolites, but also their chemical structure. However, sometimes, NMR
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can reliably detect metabolites in high concentrations. Both MS and NMR allow the assessment of
metabolites from biological fluids and tissue samples [33].
An integrative methodological approach was used by Xie et al. when they explored hepatic
transcriptome and metabolome alterations in male Wistar rats fed high fat diet (HFD) for 16 weeks.
A transcriptome analysis demonstrated that 130 genes were differentially expressed in the livers
resected from HFD-fed rodents, compared to those fed standard chow. The majority of differentially
expressed genes were intertwined in lipid synthesis and metabolism and in energy utilization.
Moreover, these authors investigated the lipid composition in both serum and hepatic tissues
through gas-chromatography/mass spectrometry as metabolomics approach, revealing an unbalanced
composition of lipids and an increase in saturated and monounsaturated fatty acids. These comparative
observations revealed that hepatic fatty acid utilization through β-oxidation is inhibited and de novo
lipogenesis (DNL) is enhanced after HFD administration in rodents [34].
Nonetheless, an unbalanced diet may induce inflammatory and metabolic stress as well, as a
result of the impaired interactions between transcription factors and nuclear receptors, thus affecting
the transcription and translation cascades. Therefore, not only should the direct effect of nutrients
on transcription be considered, but also the indirect effect caused by inflammatory and metabolic
stress. A good example to explain this effect is the regulation of Peroxisome proliferator-activated
receptor-α (PPARα). In the liver, PPARα is a transcription factor that promotes fatty acid intake
from the bloodstream and their catabolism, through β-oxidation processes. Obesity and T2D are
characterized by a chronic status of low-grade inflammation, implicating the release of cytokines,
which in turn lead to PPARα downregulation (inflammatory stress). Moreover, in obese and diabetic
individuals, the level of fatty acids is constantly elevated, constituting a metabolic stressor, further
compromising PPARα activity [27]. Thus, another important goal of nutrigenomic research is to
elucidate the double interaction of metabolic and inflammatory stressors triggered by unhealthy diet,
with physiological pathways.
The deep understanding of the genome-diet interactions may lead to the identification of
non-invasive biomarkers representative of the human nutritional status, possibly revealing individual
dietary habits in a more precise and objective way compared to questionnaires. Moreover, nutritional
biomarkers could be indicators of pathophysiological status. Well-established examples are the plasma
levels of fasting glucose, associated with diabetes, or the plasma cholesterol and triglycerides, linked
with cardiovascular disorders [30]. In the case of NAFLD, a potential nutritional biomarker could
be the serum levels of saturated fatty acids. Together with transcriptomic, proteomic, metabolomic
and lipidomic biomarkers, epigenetic modifications can be implemented as nutritional biomarkers as
well [30]. Indeed, DNA methylation, miRNAs or long-chain non-coding RNAs, modulated by dietary
patterns, have emerged as mRNA transcription regulators of pivotal importance in pathophysiological
processes [30], as precisely summarized in the following sections.
Therefore, considering the genetic background of an individual, its epigenetic signature and its
phenotypic hallmarks, through the interaction of all ‘omics,’ methodological approaches may define
an integrated Personal Omic Profile (iPOP), acquiring an enormous potential of omics integration in
medical researches, in monitoring health and personalized interventions [35].
3. Nutrigenetics: New Field to Customize Intervention Strategies
Although obesity and IR are the most prevalent risk factors for NAFLD pathogenesis, hepatic
fat content varies substantially among individuals with equivalent adiposity, indicating that other
risk factors may contribute to this condition. Indeed, epidemiological, familial and twin studies
provide evidence of a strong heritability of hepatic lipid accumulation [36,37]. In 2009, Schwimmer et
al. demonstrated that parents and siblings of overweight children with NAFLD have an increased
predisposition to develop a fatty liver compared to obese children without NAFLD [38]. Nonetheless,
it has been demonstrated that familial NASH clustering is frequent, reaching 18% of patients having a
similarly affected first degree relative [39].
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Furthermore, there is a huge inter-ethnic variability in the predisposition towards NAFLD [36,37].
Two large multi-ethnic population studies conducted in the United States revealed an higher risk of
NAFLD onset in Hispanic individuals than those of European descent, whereas African-Americans are
protected irrespectively of diabetes, excess in body weight and socioeconomic factors, consistently,
with a key role of heritability [7]. In particular, African-Americans differed in the metabolic response
to obesity and IR when compared to either Hispanics or Caucasians, appearing more resistant to
triglyceride (TG) accumulation both in the adipose tissue and in the liver [40].
To date, several inherited risk factors have been recognized to be implicated in genetic susceptibility
to develop NAFLD and its progressive forms [7]. However, the major common predictors of the
inherited predisposition to severe NAFLD are the variants in PNPLA3, TM6SF2, Glucokinase Regulator
(GCKR) and MBOAT7 genes.
Nutritional genetics or nutrigenetics highlights the impact of human genetic variations on nutrient
utilization/metabolism/processing, food tolerances and nutrient requirement [13]. It tells us how
an individual’s genetic background will shape the risks and benefits of consuming different types
of foods and nutrients [14]. Scientific advances in this field might pave the way in the future to
NAFLD prevention and treatment, predicting the individual risk, explaining personal pathophysiology
and customizing nutritional management. Furthermore, to understand the biological mechanisms
entailing genome-nutrient interactions may constitute a revolutionary frontier in the knowledge of
how common chronic human diseases are initiated or accelerated by nutrient exposure. Examples of
possible gene-diet interactions and personalized therapeutic interventions to prevent NAFLD onset
and progression are summarized in the paragraphs below.
3.1. PNPLA3: An Appealing Genetic Sensor of Dietary Compounds
The main genetic determinant of the inter-individual and ethnicity-related differences in hepatic fat
content is the rs738409 C>G variant in PNPLA3 (also known as adiponutrin), encoding the amino acid
substitution Isoleucine to Methionine at the position 148 (referred to as p.I148M) [41]. Carriers of the G
at-risk alleles are more prevalent in Hispanics than in Europeans and less frequent in African-Americans,
possibly explaining the inter-ethnic susceptibility to NAFLD. PNPLA3 is an intracellular membrane
lipase, localized mainly in the endothelial reticulum (ER) and at the surface of the lipid droplets in
hepatocytes, adipocytes and in hepatic stellate cells (HSCs) [42,43]. This inherited variant strongly
impacts on the entire spectrum of liver damage related to fatty liver, encompassing NASH, severe
fibrosis and HCC, even influencing the response to therapeutic approaches [44]. The underlying
mechanisms whereby the p.I148M variant induces steatosis development seems to be related to the
accumulation of the PNPLA3 mutated protein on the lipid droplet surface. This event may be due
to the lesser accessibility to ubiquitin ligases and to impaired proteasomal degradation of the I148M
protein forms [45]. Thus, it interferes with lipid remodeling in fatty-laden hepatocytes, even inhibiting
the activity of other lipases (i.e., PNPLA2), and accordingly, reducing TG turnover and dismissal [46].
Indeed, chronic overexpression of the PNPLA3 I148M variant in mice impairs TG hydrolysis and
depletes long-chain PUFA [47]. In HSCs, conversely, the PNPLA3 I148M variant alters retinol secretion,
potentially contributing directly to fibrogenesis and carcinogenesis, increasing the risk for cirrhosis
and HCC development, independently of the predisposition to steatosis [48–50]. The size effect of the
p.I148M variant on the risk of NAFLD is the strongest ever reported for a common variant, modifying
the genetic susceptibility of NAFLD and liver disease progression [6].
It has been demonstrated that the accumulation of the mutated I148M protein may be triggered
by environmental factors. At a nutritional level, PNPLA3 expression is transcriptionally modulated by
the activation of the Sterol regulatory element-binding protein 1 (SREBP1c)/Liver X Receptor (LXR)
pathway induced by hyperinsulinemia and by carbohydrate feeding. Moreover, PNPLA3 protein
degradation can be inhibited by the presence of fatty acids [51,52].
In an intriguing study, Santoro et al. revealed the presence of an interaction between PNPLA3
rs738409 variant and the dietary ratio of omega-6/omega-3 polyunsaturated fatty acids (PUFA) on
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hepatic fat content and alanine aminotransferase (ALT), in 127 pediatric NAFLD patients of various
ethnicities (58 Caucasians, 30 African-Americans and 39 Hispanics) [53]. Patients homozygous for
the minor G allele ameliorated steatosis and liver enzymes after omega-3 consumption, due to the
inhibition of hydrolyzing n-9 fatty acids in presence of the p.I148M variant. Indeed, the presence
of the rs738409 variant may hinder the PNPLA3 hydrolytic function, lowering the protein ability in
hydrolyzing the n-9 of about 15% [54]. The n-9 can be derived directly from diet (i.e., meat, olive oil,
sesame oil, almonds and avocados) or they are synthesized starting from n-6 PUFA [55]. All these
observations suggest that increasing dietary intake of foods rich in n-3 PUFA such as salmon, tuna and
flaxseed oil, or supplementing the diet with n-3 PUFA respect to n-6 PUFA could provide a targeted
therapy to subjects with NAFLD homozygous for the G allele [53]. Indeed, n-6 overload may serve
as substrate for TG synthesis, further accelerating hepatic steatosis and in the meantime, it delays
the hydrolytic function of the PNPLA3. The remnant n-6 not incorporated into TG may lead to the
over-production of pro-inflammatory omega 6-derived species, triggering the switching from simple
steatosis to NASH. Moreover, an excess of free fatty acids (FFAs) enhanced hepatic TG accumulation in
the presence of the p.I148M variant, significantly down-modulating lipid hydrolyzation [56].
Conversely, in the double-blind placebo controlled WELCOME trial (NCT00760513), 103 adult
patients with NAFLD were randomized to receive a supplementation of omega-3 fatty acids (long chain
PUFA), including docosahexaenoic (DHA) and eicosapentanoic acid (EPA) or placebo for 15–18 months.
PNPLA3 homozygous patients displayed an independent association with a decrease percentage of
DHA tissue enrichment during the trial but did not with changes in serum TG concentration [57].
Consistently, in another randomized controlled trial (NCT00885313), it was tested whether the PNPLA3
I148M variant is associated with the response to DHA (250 or 500 mg/day) in 60 children with NAFLD
for 24 months. This study demonstrated that the 148M allele is associated with no beneficial effect
of DHA supplementation regarding liver fat, showing a double risk of severe steatosis at the end
of the trial [58]. These findings clarify the data reported by Santoro et al., showing that PNPLA3 is
implicated in omega-3 fatty acid mobilization in the livers [53]. In turn, omega-3 fatty acids may
down-modulate SREBP1c expression and PNPLA3 148M variant is associated with lower DNL despite
the substantial increased hepatic fat content, thus explaining the lower response to DHA+EPA therapy
in these patients [59].
Furthermore, in 153 overweight Hispanic children, Davis et al. revealed that the hepatic fat
fraction in carriers of the GG genotype is strongly influenced by carbohydrate and total sugar dietary
intake (clinical trials NCT00697580 195-1642394A1 and NCT00693511) [60]. Indeed, high dietary sugar
consumption may induce SREBP1c and, in turn, PNPLA3 mutated protein expression exacerbating fat
deposition [60]. Moreover, low carbohydrate diet consumption for 6 days exerts a greater impact on
liver fat content in PNPLA3 148MM subjects (trial registered as 233,775 at www.hus.fi) [61]. Similarly,
in 200 adolescents, Nobili et al. demonstrated that the moderate intake of sweetened beverages led to
increased hepatic fat deposition in PNPLA3 homozygous, and hampered consumption of vegetables
declined the risk of severe steatosis, thus reporting a possible interaction between PNPLA3 I148M and
dietary components regarding the severity of steatosis [62].
In obese children carrying wild-type allele, weight loss predisposes to more effective benefits on
intra-hepatic fat content and liver enzymes [63].
Overall, this evidence may support the notion that dietary interventions may exert various effect
in NAFLD patients depending on their genetic background.
3.2. TM6SF2: Two Sides of the Same Coin
The low-frequency rs58542926 C>T variant in TM6SF2, encoding the loss-of-function mutation
referred to as p.E167K is another determinant of progressive NAFLD [64]. The likely mechanism
through which the E167K variant predisposes to an increase in hepatic fat content seems to be related to
the retention of lipids and the impairment of very low-density lipoprotein (VLDL) release by the liver.
Moreover, TM6SF2 rs58542926 variation modulates the hepatic fat content, impairing lipid synthesis
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from PUFAs [65]. Indeed, TM6SF2 is mainly implicated in TG-rich lipoprotein lipidation and secretion
and it is mainly expressed in small intestine and in the liver. Patients carrying the T minor allele
display increased aminotransferase concentrations, low serum lipoproteins and steatosis development.
Conversely, by reducing circulating lipids, the E167K variant decreases the risk of cardiovascular
events in both children and adults [66–68].
O’Hare et al. demonstrated that subjects carrying the T allele display improved fasting and
postprandial lipid profiles, even after a high fat challenge, in a cohort of 3556 individuals enrolled
in the Amish Complex Disease Research Program (ACDRP). In addition, these authors investigated
the impact of TM6SF2 deficiency in a zebrafish model and in cultured human Caco-2 cell lines,
in which they revealed that TM6SF2 loss of function decreased lipid clearance and, in turn, favors TG
accumulation and ER stress in enterocytes. All these findings support the crucial role of TM6SF2 in
dietary lipid metabolism in small intestine, exerting a similar function in the lipidation and release
of both hepatically- and intestinally-derived TG-rich lipoproteins [69]. Nonetheless, concerning the
postprandial glucose homeostasis, Musso et al. correlated the presence of TM6SF2 variation with
increased hepatic and adipose IR, impaired pancreatic β-cell function and higher muscle insulin
sensitivity and whole-body fat oxidation rate [70]. Moreover, the T-allele entailed a lower postprandial
lipemia, a less atherogenic lipoprotein profile, and a postprandial cholesterol redistribution from smaller
atherogenic lipoprotein subfractions to larger intestinal and hepatic VLDL subfractions [70]. Therefore,
these authors demonstrated that the TM6SF2 C>T polymorphism affects not only the postprandial
lipoprotein metabolism, but also the nutrient oxidation, glucose tolerance and the gastrointestinal
response to fat ingestion [70].
However, Krawczyk et al. reported that TM6SF2 variant as well as PNPLA3 variation did not
impair the response to low-calorie four-month dietetic intervention in 143 NAFLD patients [71]. Indeed,
the dietary interventions improved phenotypic traits, steatosis and ALT concentrations independently
of the presence of these two variants [71]. Finally, Dongiovanni et al. revealed that the rs58542926
TM6SF2 variant did not impact on the beneficial effect of statins administration in NAFLD patients [72],
opening the possibility to treat T allele carriers with statins to ameliorate liver damage, even if the lipid
profile of these patients does not encourage this therapeutic strategy [67].
3.3. GCKR: A Potential Carbohydrates’ Modulator to Improve Liver Damage
Besides PNPLA3 and TM6SF2 variations, the common loss-of-function rs1260326 variant in the
GCKR gene, encoding the p.P446L substitution, has been widely associated with increased fasting
TG concentrations, steatosis and liver damage. This protein physiologically regulates glucose influx
into the hepatocytes, mediating the activation of DNL. The alteration of GCKR impairs its ability to
negatively modulate glucokinase, constitutively activating the hepatic glucose uptake. On one side,
this event may improve circulating fasting glucose and insulin concentrations; on the other, it may
favor glycolysis and steatosis onset, by providing malonyl-CoA as substrate for DNL and by blocking
fatty acid oxidation [73–75].
Several studies have explored the interaction between GCKR rs1260326 variant and the
environmental factors [74,76,77]. In an open-labeled and single-arm clinical trial, Kaliora et al.
demonstrated that T allele carriers respond better to nutritional intervention in terms of fasting
blood glucose levels compared to non-carriers, in 44 overweight adults with NAFLD which have
been received dietary counseling for six months [76]. For instance, whole-grain supplementation is
associated with lower fasting glucose and insulin concentrations independently of demographics, other
dietary and lifestyle factors and BMI [78]. An interesting interaction between the GCKR variation and
whole grain intake has been proposed by Nettleton et al. These authors demonstrated that a greater
whole-grain intake is even more strictly associated with the reduction in fasting insulin concentrations
in patients carrying the at risk allele [78].
Moreover, Santoro et al. reported for the first time the rate of DNL through incorporation of
deuterium into the palmitate contained in the VLDL after the administration of a carbohydrate drink
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(75 g glucose and 25 g fructose) in obese adolescents. These authors demonstrated that the GCKR
rs1260326 variation in homozygosity increased hepatic lipid synthesis in obese adolescents, as a result
of the enhanced glycolytic carbon flux to TG formation [74]. This study was the first that revealed in
pediatric subjects that a common variant might favor steatosis onset by enhancing the ability of the
liver to convert carbohydrate into TG, raising the possibility to decrease glucose and fructose dietary
intake in patients homozygous for the rs1260326 variant to improve liver damage [74]. Indeed, it has
been elucidated that the adherence to the Mediterranean diet (MedDiet) may modulate the detrimental
effect of rs1260326 variant by hampering circulating lipids [79]. Consistently, the association between
GCKR genotype and serum total cholesterol in children is modulated by dietary monounsaturated
fatty acid relative to saturated fatty acid (MUFA:SFA) ratio [80].
3.4. MBOAT7 as a Novel High-Sensitive Converter of Nutritional Substrates
In 2005, a genome-wide association study (GWAS) revealed that the novel common rs641738
C>T variant in the MBOAT7-TMC4 locus on chromosome 19 increased the susceptibility to alcoholic
cirrhosis in heavy drinkers [81]. Then, it has been demonstrated that rs641738 variation is associated
with a strong predisposition towards hepatic fat accumulation and to the entire spectrum of liver
damage related to NAFLD, including HCC [82,83]. Notably, it has been identified as a risk factor for
fibrosis development in viral hepatitis B and C, possibly representing a common modifier of liver
damage [84,85].
MBOAT7, also known as lyso-phosphatidylinositol (lyso-PI) acyl-transferase1 (LPIAT1), encodes
for an enzyme member of the “Lands’ Cycle” of phospholipid acyl-chain remodeling of the membranes.
It is mainly localized in the mitochondria-associated membrane (MAM), which is the membrane
bridging ER and mitochondria in which the fat biosynthesis and lipid droplets formation occurs.
It conjugates an acyl-CoA to the second acyl-chain of lyso-phospholipids, using as preferential substrate
the arachidonoyl-CoA. Thus, it regulates the desaturation of phospholipids and the amount of free
arachidonic acid, a precursor of proinflammatory mediators (eicosanoids) [86]. It has been made clear
that the likely mechanisms behind the association between the rs641738 variant and liver damage
is related to the hampered hepatic gene and protein expression of MBOAT7, determining changes
in phosphatidylinositol species [82,87]. Furthermore, we have recently pointed out that hepatic
MBOAT7 down-regulation is a dysfunctional response to inherited or diet-induced hyperinsulinemia
and that its reduced expression is enable to induce intracellular fat accumulation in clinical samples, in
in vivo models of NAFLD and in genetically edited HepG2 cells (MBOAT7-/-) [87]. Specifically, in the
overweight adults, MBOAT7 is hampered in the presence of hyperinsulinemia and severe liver damage,
independently of the genetic background. These findings have been even more clear in experimental
models of NAFLD, in which the reduction of MBOAT7 expression is stronger during obesity and IR.
Consistently, even fructose administration reduces hepatic Mboat7 in rodents (unpublished data).
During post-prandial or pathological hyperinsulinemia and in carriers of the T allele, MBOAT7
expression and function is impaired, contributing to the increase of saturated phospholipids.
The accumulation of these compounds, mainly phosphatidylinositol species, may be shunted to
the synthesis of saturated and mono-unsaturated TG, further corroborating fat deposition. This
process requires the upregulation of the fatty acid transporter (FATP1) and the consequent fatty acid
uptake. According to this notion, FATP1 genetic deletion rescued the intracellular fat accumulation
and the increased lipogenesis observed in the MBOAT7-/- background [87]. Our novel evidence may
introduce the idea that a well-balanced diet, characterized by low carbohydrate and saturated fatty
acid consumption, may influence the genetic susceptibility to develop fatty liver in carriers of the
rs641738 variant. These notions pave the way to improve our knowledge about the influence of macro
and micronutrients on this genetic substrate, emphasizing the concept that it may provide a new
example of gene-environment interaction, which should be deeply explored in future studies.
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3.5. Other NAFLD Genetic Risk Factors Responsive to Diet
In 2014, Miele et al. conducted for the first time a case–control study on the effect of metabolic
gene polymorphisms, nutrition and their interaction on the risk of NAFLD in 294 Italian cases and 359
controls [88]. These authors reported that young adults and males display an increased risk of NAFLD,
as well as those subjects which consume an unbalanced diet. Oxidative stress and mitochondrial
dysfunction are hallmarks of severe NAFLD. Therefore, the authors examined the interaction between
dietary factors and inherited variants in genes that exert key roles as antioxidant defense, such as
glutathione S-transferase Mu 1 (GSTM1), glutathione S-transferase theta 1 (GSTT1), cytochrome P450
superfamily members and sulfotransferase 1A1 (SULT1A1). They found that these inherited factors
significantly interact with high fruit intake (more than two fruits/day) or high grilled meat/fish
consumption (more than once per week), exasperating the risk of developing NAFLD and suggesting
a possible role of aromatic hydrocarbons in liver steatosis [88].
Another important study investigated the response to diets depending on individual genetic
backgrounds by exploiting the nutrient-induced insulin output ratio (NIOR) in order to identify
patients phenotypically sensitive to glucose or fat in the diet [89]. In this paper, the authors examined
the polymorphisms linked with NIOR according to their impact on the output of insulin after a meal
in 171 patients, after which they create a nutritional plan to follow for 6 months. The reduction of
total and hepatic fat mass was most effective in the group in which the amount of dietary fat or sugar
was adjusted to gene polymorphisms, among which Adrenergic receptor (b3AR), Tumor necrosis factor α
(TNFα), Apolipoprotein C3 (Apo C3), Uncoupling Protein type I (UCP-1), Peroxisome proliferator activated
receptor (PPAR)γ 2 and Apolipoprotein E (APOE) [89].
Recently, Dongiovanni et al. demonstrated that Proprotein Convertase Subtilisin/Kexin Type 7 (PCSK7)
rs236918 G>C variant impacts on circulating lipids and liver damage in a large cohort of NAFLD
patients [90]. In this cohort, the variant did not impact on hepatic fat accumulation, but stratifying
patients for the PNPLA3 I148M risk variant, the rs236918 variation seems to be also associated with
more severe steatosis. In particular, in HepG2 cells, PCSK7 genetic deletion reduced lipogenesis,
fat accumulation, inflammation and fibrogenesis, even after the exposure to FFAs challenge [90].
Huang et al. investigated in 730 obese adults whether two-year weight-loss diets modified the effect
of PCSK7 rs236918 genetic variant on changes in fasting insulin levels and IR in the randomized,
controlled Preventing Overweight Using Novel Dietary Strategies (POUNDS) LOST clinical trial
(NCT00072995) [91]. The minor C allele was found significantly correlated with a strong increase in
fasting insulin levels and HOMA-IR in response to high-carbohydrate diet consumption, providing
novel information in guiding dietary intervention in diabetic patients. Nonetheless, alterations in
PCSK9, another member of the Proprotein Convertase Subtilisin/Kexin family, have been broadly
associated with familial hypercholesterolemia [92], severe steatosis [93] and cardiovascular risk [94], as
a consequence of its role in the modulation of low-density lipoprotein (LDL) uptake. PCSK9 expression
is strongly influenced by nutritional status. Indeed, PCSK9 mRNA levels impressively decrease in
mice after 24 h of fasting and in turn, its expression is restored via SREBP1c activation upon high
carbohydrate refeeding or insulin stimulation [95].
Finally, the rs4841132 G>A variant, enhancing the expression of Protein Phosphatase 1 Regulatory
subunit 3B (PPP1R3B), which is involved in glycogen synthesis, has been recently reported to
reduce the risk of NAFLD, but at the same time, may favor liver disease by facilitating glycogen
accumulation [96,97]. Conversely, in a rodent model, hepatic genetic deletion of PPP1R3B significantly
reduced glycogen synthase protein abundance, glucose incorporation into hepatic glycogen, total
hepatic glycogen content and fasting plasma glucose compared to wild-type littermates [98]. Thus,
a low-carbohydrate dietary approach and an active lifestyle in patients carrying the rs4841132 variant
may improve hepatic glycogen accumulation.
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4. Nutriepigenomics: Is It Worth Looking into?
Epigenetic modifiers in NAFLD can represent novel molecular predictors, which can determine
not only the early risk assessment, but also the disease progression and prognosis, providing a new
perspective on NAFLD management. Epigenetics is a hereditable but reversible phenomenon that
affects chromatin ultrastructure and transcription without modifying DNA sequence in response
to environmental cues including DNA methylation, histone modifications and miRNAs targeting
mRNA [6,9].
The emerging knowledge of ‘nutriepigenomics,’ referred to as the interaction between nutrients
and genome through epigenetic mechanisms, is increasingly grabbing attention in the field of human
complex diseases as MetS, neurological disorders and cancer [99]. The hypothesis of the Developmental
Origins of Adult Health and Disease underlined that the exposure in utero to environmental stressors,
such as diet, had intergenerational effects, compromising adult phenotype [100].
Hence, food intake could affect epigenome remodeling throughout life and, interestingly, several
dietary habits could be critical during gestational and post-natal periods, leading to stable epigenetic
changes, which, in turn, could impact metabolic disease susceptibility [6,99]. Likewise, it has been
reported in both animals and humans that risk factors, such as maternal obesity, could predispose
descendants to metabolic disorders due to an imprinted metabolic signature induced on microbiota
during pregnancy [99]. Low protein (LP) diet administered in the second half of gestation has been
associated with aberrant renin-angiotensin system as a consequence of epigenetic reprogramming,
inducing CpG islands hypomethylation and miRNAs deregulation in the offspring [101]. Fat-enriched
diets consumed in pregnancy may favor chronic-low grade inflammatory state into the placenta and
in many organs of the offspring, among which the liver, leading to hepatic metabolic changes and
contributing to steatosis. For instance, maternal HFD alters littermates’ DNA methylation, influencing
genes involved in NASH pathogenesis and hepatic fibrosis [102,103].
Caloric restriction and lifestyle are the only available interventions for NAFLD management. Since
epigenetics are reversible processes, selective diets based on specific micro/macro-nutrients modulating
the epigenetic pattern could be encouraging for novel non-invasive and cost-effective approaches to
ameliorate NAFLD and prevent its progression. Therefore, this chapter will summarize the main
notions about diet-epigenome interplay that may be involved in the pathogenesis of NAFLD, paying
attention to the lesser-known aspects, including the role of gut microbiota and the emerging therapies.
4.1. DNA Methylation: from NAFLD towards HCC
Aberrant pattern in DNA methylation may arise during NAFLD development, affecting nuclear
DNA or mitochondrial DNA (mtDNA), and differentially methylated genes may disentangle simple
steatosis from NASH [104]. For instance, it has been observed that biopsy-proven NASH patients had
higher methylation levels of Mitochondrially encoded NADH dehydrogenase 6 (MT-ND6) than individuals
with simple steatosis and they correlated with NAFLD activity score (NAS) [105]. The enzymes
involved in DNA methylation reaction are members of the DNA methyltransferases (DNMTs) family,
which transfer a methyl group from S-adenyl methionine (SAM) to the fifth carbon of a cytosine (5mC)
preceding a guanine nucleotide or CpG clusters. In humans, hepatic DNMT levels are increased in
subjects affected by NASH and are significantly associated with histological liver damage severity [105].
Generally, CpG islands are enriched in promoter regions of the genes, thus representing a crucial
mechanism that regulates gene expression [106]. Hypermethylation of CpG islands is generally linked
to gene silencing, while hypomethylation of promoters may activate transcription.
Deficiency in several dietary compound donors of methyl group, such as betaine, choline, vitamin
B12 and folate, are associated with alterations in DNA methylation and may favor progressive NAFLD.
Conversely, it has been shown that nutritional interventions and methyl donors’ supplementation
improved body weight, insulin sensitivity and fat accumulation in the liver. Cordero et al. investigated
the effects of methyl donors added to a high-fat-sucrose (HFS) diet on key regulatory genes involved
in NAFLD. They found that HFS diet enriched of choline, betaine, vitamin B12 and folic acid induced
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fatty acid synthetase (FASN) hypermethylation in the livers of rats, improving TG accumulation [107].
Choline-deficient diet (ChDD) induced a reduction in PPARα expression, and its lower levels were
correlated to high methylation in PPARα promoter [108]. Betaine, a lipotropic agent, has shown
beneficial effects to revert HFD-induced hepatic steatosis acting on global methylome and, in detail,
supports hypomethylation of CpG clusters in the microsomal triglyceride transfer protein (MTTP)
promoter, which is involved in VLDL assembly and secretion [109]. Rats fed a diet without vitamin
B12 and folate predominantly developed micro-vesicular steatosis, increased TG levels and impaired
mitochondrial fatty acidsβ-oxidation, and these changes were due to the hypomethylation of Peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PCG1-α).
Methyl-deficient and obesogenic diets were also associated with far-reaching epigenetic changes
leading to advanced liver injury and cancer development. Either calcium or magnesium deficient diets
during gestation and nursing influence hepatic methylation of the 11β-hydroxysteroid dehydrogenase
(Hsd11b) gene type 1 and 2 of the offspring, contributing to prenatal susceptibility to IR and metabolic
complications [110,111]. Dudley et al. suggested that hypomethylation of hepatic cell cycle inhibitor
Cyclin Dependent Kinase Inhibitor 1A (Cdkn1a) is one of the earliest epigenetic changes occurring in pups
born from HFD-fed dams predisposing the offspring to long-term hepatic dysfunction [112]. Rats fed a
diet containing low methionine and lacking both choline and folic acid highlighted an early activation
of the DNA repair genes and pronounced loss of DNA methylation that promote the progression to
liver carcinogenesis [113].
Zeybel et al. isolated genomic DNA from percutaneous needle biopsies of patients with mild or
severe NAFLD and identified significant differences across several CpGs islands within fibrosis-related
genes, among which transforming growth factor beta 1 (TGFβ1), Type I Collagen α1 (Col1A1) and
Platelet-derived growth factor (PDGFα) [114]. Notably, Murphy et al. observed 69,247 differentially
methylated CpG sites in patients with advanced versus mild NAFLD and found a correlation between
methylome data with transcriptome ones. In particular, hypomethylated genes matched with higher
mRNA levels in advanced NAFLD individuals compared to those with mild NAFLD. Among these
genes, altered methylation of Fibroblast growth factor receptor 2 (FGFR2) and Caspase 1 (CASP1), which
are involved in epithelial to mesenchymal transition, inflammation and fibrotic processes, seemed to
play a crucial role in the progression to cirrhosis and HCC [104].
4.2. Histone Modifications in NAFLD: Dietary Control of Chromatin Reorganization
Post-translational modification of histones is an essential mechanism to determine chromatin
architecture, in terms of DNA packaging and accessibility, and gene expression. As the other epigenetic
processes, it occurs in response to environmental cues and includes dynamic changes of aminoacidic
residues in the histone tails as: 1) acetylation/deacetylation of lysine; 2) phosphorylation of serine,
threonine and tyrosine; 3) methylation of the side chains of lysine and arginine; 4) other mechanisms
among which deimination, ADP ribosylation, ubiquitylation, sumoylation, proline isomerization and
the addition of β-N-acetylglucosamine [115].
Several enzymes that participate in histone modifications are associated with the epigenetic
control of metabolic pathways. For instance, JHDM2A-/- mice, which are deficient of jumonji C
(JmjC)-domain-containing histone demethylase 2A (Jhdm2a), develop hallmarks of MetS, such as obesity,
hyperglycaemia, hypercholesterolemia, hyperinsulinemia [116]. Fetal intrauterine growth restriction
(IUGR) occurring during pregnancy and lactation determined biochemical abnormalities in adult rat
offspring. Indeed, LP-fed rat dams led to high levels of cholesterol in the offspring and reduced the
fetal expression of Jhdm2a, thus conditioning the hepatic lysine 9 acetylation of histone H3 (H3K9) in
the Cholesterol 7α-hydroxylase (Cyp7a1) promoter, which catabolizes cholesterol to bile acids [117].
Sirtuin (Sirt) 1, involved in DNA repair, appetite control and in the crosstalk between adipose tissue
and the liver, is considered a key epigenetic modifier in the pathophysiology of obesity and NAFLD.
In response to caloric restriction, Sirt1 induces histone and non-histone deacetylation of its target genes,
such as PCG1-α and TP53 to adapt gene expression to metabolic activity, IR and inflammation in the
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adipose tissue. In the liver, Sirt1 supports gluconeogenesis via PCG1-α and Forkhead box O1 (FOXO1),
promotes fatty acid oxidation through PPARα and inhibits DNL by SREBP1c degradation [118].
Bisphenol A (BPA) administered in Sprague Dawley rats during the pregnancy and breastfeeding
period induced an increment of body weight and development of micro-vesicular steatosis in the male
littermates further challenged with HFD. These metabolic alterations were coupled with sex-specific
epigenetic modifications among which the reduced K4 dimethylation at histone H3 (H3Me2K4), which
led to lower carnitine palmitoyl transferase 1A (Cpt1a) mRNA expression dysregulating mitochondrial
β-oxidation. In addition, macroH2A1.1, a variant of histone H2A, whose expression is Sirt1-dependent,
protects hepatocytes against lipid accumulation in mice [119,120]. Mice lacking Sirt3 (SIRT3KO), the
main mitochondrial protein deacetylase, accelerated obesity, IR and NASH development in response
to chronic HFD exposure. According to these results, patients carrying the rs11246020 variant (V208I)
in SIRT3 gene increased susceptibility to develop MetS [121]. Furthermore, HFD per se suppressed
Sirt3 expression in mice inducing global hyperacetylation of mitochondrial proteins [121].
Chung et al. found a novel histone acetyltransferase (HAT) inhibitor, the tannic acid (TA),
a plant-derived hydrolysable tannin polyphenol and tested its efficacy in both in vitro and in vivo.
TA administration showed anti-lipogenic effects, by blocking the hyperacetylation of lysine 9 and 36 at
histone H3 (H3K9 and H3K36) in the promoter of DNL genes (SREBP1c, FASN and ATP citrate lyase
(ACLY)), thus improving NAFLD [120,122]. Moreover, Tian et al. identified the histone deacetylase
8 (Hdac8) as a novel chromatin modifier in dietary models of NASH and HCC and in humans.
Post-prandially activated Srebp1 lead to Hdac8 expression which interacts with the polycomb protein
enhancer of zeste homolog 2 (Ezh2) to promote aberrant cell proliferation. Both in rodents and in
patients with NAFLD-HCC, the HDAC8/EZH2 complex controls histone H4 acetylation and works
as epigenetic silencing machinery on inhibitors of Wingless-related integration site (Wnt)/β-catenin
signaling, thus favoring HCC development [123].
4.3. miRNAs-Diet Crosstalk in NAFLD: How Unhealthy Dietary Habits Act at Multiple Levels
miRNAs are short non-protein coding, single-strands RNAs of 19–22 nucleotides, that can target
mRNAs through complementary base-pairing, thereby leading to the post-transcriptional repression
of targeted protein-coding genes [124]. miRNAs can target multiple genes (multi-functionality) or
multiple miRNAs can modulate a single gene (redundancy), suggesting that miRNAs have an extensive
regulatory capacity and a profound impact on health and disease [124,125].
miRNAs may regulate a wide spectrum of biological processes and metabolic homeostasis,
including lipid synthesis, fatty acids and glucose catabolism, inflammation, proliferation, apoptosis
and necrosis, which have been known to be epigenetically deregulated in NAFLD, NASH and HCC [126].
Furthermore, it has been shown that circulating miRNAs may mirror the histological features and the
molecular events occurring in NAFLD, thus, representing a turning point for non-invasive diagnosis
and clinical monitoring of the disease progression [8–11,127,128]. Unhealthy diets affect adiposity and
may accelerate NAFLD development in both animals and humans by altering miRNAs, which are
susceptible to environmental challenge. We have previously reported in detail the miRNA signature
associated with the spectrum of NAFLD, from simple steatosis towards cirrhosis and HCC [9]. Thus,
in this chapter, we will summarize the main findings about miRNAs-diet alteration related to NAFLD
onset and progression.
miR-122, the most abundant miRNA in human liver [9,129], has been proposed as a marker of
NASH and disease severity and it has been demonstrated to be highly responsive to diet in in vitro
and in vivo models as well as in humans. In genetically improved farmed tilapia (GIFT, Oreochromis
niloticus) fed either a normal or high-lipid diet, inhibition of hepatic miR-122 led to upregulation
of lipogenic genes, among which stearoyl-CoA desaturase gene (SCD) at the 3′-UTR region, thereby
affecting lipid metabolism and contributing to fat accumulation [130]. In contrast, Long et al. found
that FFAs or HFD upregulated miR-122 in hepatocytes-derived HepG2 and HuH7 cell lines and in mice,
respectively, revealing that miR-122 may promote lipogenesis by suppressing Sirt1. Indeed, miR-122
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knockdown mitigated hepatic steatosis via Sirt1-induced liver kinase B1/AMP-activated protein kinase
(LKB1/AMPK) pathway [131].
HepG2 cell line exposed to palmitic acid (PA) upregulates miR-181b, which acts as a repressor
of SIRT1 mRNA at 3′-UTR. In presence of a mixture of fatty acids, human normal L02 hepatocytes
increased miR-34a levels and, in parallel, downregulated its target genes [132]. Similarly, steatogenic
diets as HFD reduced Sirt1 and PPARα expression and overexpressed both miR-181b and miR34a in
mice livers, thus supporting the crucial role of these miRNAs to promote steatosis [132,133]. It has also
been reported that miR-34a inhibits β-Klotho, a co-receptor of the fibroblast growth factor 19 (FGF19),
implicated in glucose metabolism during post-prandial response in physiological status. The reduction
of β-Klotho plasma levels has been recently associated with lobular inflammation, ballooning and
fibrosis in NAFLD pediatric patients [134]. Therefore, the inhibition of miR-34a restoresβ-Klotho/FGF19
signaling and improves obesity in ob/ob mice [9,126,132]. It has been showed that miR-155 is highly
expressed in hepatocytes and Kupffer cells (KCs) isolated from methionine-choline deficient (MCD)-fed
mice [135,136], playing an important role in early hepatic lipid storage by targeting LXRα and favoring
a pro-inflammatory response [135,136]. miR-21 is one of the most up-regulated miRNAs in serum
and hepatic tissues of individuals with fibrosing-NASH and HCC [137,138]. Furthermore, it has been
shown that lipogenic folate and choline-deficient diet induced NASH-specific changes of miRNAs,
including miR-29c, miR-34a, miR-122, miR-134a, miR-155, miR-181a, miR-192, miR-200b, miR-409-3p,
miR-410 and miR-495 in the livers of rodents [139,140].
We have recently explored the mechanisms through which genetics, epigenetics and environmental
factors interact to promote advanced NAFLD in mice haplo-insufficient for the insulin receptor
(InsR+/-) [8]. To this end, we performed whole transcriptome analysis in HSCs isolated from both
wild-type and InsR+/−mice and found 36 differentially expressed miRNAs, which were implicated
in metabolic, fibrotic and carcinogenic processes. Next, InsR+/- mice were fed an MCD diet to
induce NASH, and we assessed the effect of diet-genotype interaction on hepatic miRNA expressions.
We found that miR-101-3p downregulation significantly associated with the whole spectrum of liver
damage and its reduction was not only InsR-dependent but even more exacerbated in the presence
of MCD diet. Likewise, we confirmed these findings in both primary InsR+/- hepatocytes and HSCs
isolated from mice and treated with fatty acids. Finally, we transfected HepG2 and LX-2 cells with
miR-101-3p mimic and demonstrated that miR-101-3p overexpression dampened proliferation and
migration, supporting the involvement of miR-101-3p in the epithelial mesenchymal transition to
promote liver cancer [8].
5. Role of Gut Microbiota in NAFLD Pathogenesis and Possible Dietary-Based Strategies
The human gastrointestinal lumen is the largest reservoir of microorganisms in the body,
representing the physiological habitat for more than 100 trillion microorganisms (bacteria, archaea,
fungi, yeast and viruses) [141]. Among them, 85% of total bacteria are commensal microbes that
live in synergy with the host, providing biological and metabolic functions. The majority of bacteria
belongs to the phyla Firmicutes (Gram positive) and to Bacterioidetes (Gram negative), mainly involved
in the short-chain fatty acids (SCFAs), i.e., acetate, butyrate and propionate and hydrogen production,
respectively [10,11]. Although the crucial role of intestinal flora remains under definition, growing
evidence demonstrates that microbial species are directly implicated in the processing and digestion of
complex and indigestible polysaccharides to SCFAs, guaranteeing the energy supply to the host and
the intestinal barrier preservation. Indeed, in physiological conditions, gut microbiota intervenes in
the formation of these end-products from plant polysaccharides catabolism, which are then absorbed
and delivered to the liver, where they are assembled in more structured lipids [10,11].
All abnormalities in intestinal flora taxonomic composition and/or function are usually referred to
as ‘dysbiosis,’ a condition that has been largely explored in rodents and in NAFLD patients [10,11].
The dietary habits along with the caloric intake may strikingly contribute to the inter-individual
variability of the intestinal bacterial strains. Indeed, a diet composition unbalanced in animal fat and
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sugars may more strongly increase the personal susceptibility to pathogenic bacteria over-growth,
exerting a detrimental effect on the immunological tolerance of mucosal cells, as shown in a large
number of preclinical [142,143] and clinical studies [144,145]. In particular, Western diet and HFD
have been related to the increased amount of pro-inflammatory bacterial species, altering gut barrier
integrity, intestinal pH and lipopolysaccharide (LPS) transition into the blood flow (endotoxemia) [146].
Indeed, the intestinal barrier is constituted by tight and adherent junctions and desmosomes, which
hold together the epithelial cells and regulate the bidirectional flux between the gut and the liver.
Specifically, intestinal barrier protects the host from pathogen invasions and impedes microbial
systemic translocation [10]. Therefore, the erosion of the protective mucus layer, the reduction of
antimicrobial mediators and microbial dysbiosis have been correlated with viable pathogenic bacteria,
Gram-negative microbial products and pro-inflammatory luminal metabolites translocation into the
blood circulation, contributing to liver damage [147,148]. The increased concentration of circulating
LPS leads to the activation of Toll-like receptor 4 (TLR4)/nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) signaling, which drives, in turn, pro-inflammatory cytokines release,
reactive oxygen species (ROS) production and oxidative stress. This event cascade may trigger the
activation of resident macrophages, the KCs and HSCs, further corroborating inflammation and fibrosis
into the liver [135,149]. Moreover, several endogenous molecules, such as as ethanol, ammonia and
acetaldehyde, whose circulating increased levels result from dysbiotic microbiota (i.e., Escherichia coli
abundance), are able to stimulate hepatic KCs to produce pro-inflammatory cytokines with similar
mechanisms occurring in alcohol-induced liver damage [10,150].
An impairment in gut barrier function and a decrease in SCFA-producing agents have also
been observed after a chronic fructose consumption, which foster macrophage activation in the liver
through TLRs and Myeloid differentiation factor 88 (Myd88)-dependent pro-inflammatory pathways
in mice [151]. Similarly, acute and chronic high fructose administration exacerbated endotoxemia in
pediatric NAFLD patients and correlated with liver inflammation [152].
Dietary modifications can rapidly normalize intestinal microbiota, thus representing a simple and
effective approach to restore eubiosis. Indeed, the diet is enabled to profoundly reshape the microbiota
composition within a few hours. People consuming a Western diet and subjects with high-fiber dietary
habits display a tremendous difference in microflora taxonomic composition, as shown in an elegant
study in which American volunteers were randomized to receive an animal-based diet (meats, eggs
and cheese) or a plant-based diet (cereals, legumes, fruits and vegetables). In individuals under
animal-based regimen, an increase in bile-tolerant species such as Alistipes, Bilophila and Bacteroides
and a reduction of Roseburia, Eubacterium rectale and Ruminococcus bromii, which metabolizes dietary
plant polysaccharides, was observed [153,154]. In this context, a diet supplemented in fibers may
favor enormous benefits for health as a consequence of their intestinal fermentation into SCFAs,
mediated by colonic bacteria. Indeed, fecal samples of vegan and vegetarian individuals showed a
significant decrease in Bidifobacterium and Bacteroides species, as well as Africans fed a high-carbohydrate
vegetarian diet compared to English subjects assuming a mixed Western diet [155,156]. Nonetheless,
a diet enriched in fibers and carbohydrates lowered fecal pH, mainly due to the products of gut
fermentative metabolism and the hampered growth of pathogens along with Escherichia coli and
Enterobacteriacee [157,158].
Finally, natural extracts, such as polyphenols provided by coffee, green tea and chocolate, have
been demonstrated to induce beneficial effects by directly interacting with gut microbial communities.
In C57Bl/6 mice fed HFD, grape polyphenols administration improved insulin sensitivity, attenuated
inflammation and ameliorated intestinal barrier integrity. Overall, diets enriched in phenols have been
associated with improved MetS features and immune tolerance, and with the restoration of intestinal
barrier function, by promoting eubiosis.
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Changes in Gut Microbiota Species Alters the Hepatic Epigenetic Landscape: A Tipping Point
It is a common knowledge that nutrition strongly influences microbiome composition, but it is
less known that there is a long-term and persistent impact of intestinal bacteria changes on hepatic
epigenome, a mechanism termed the “priming effect.” Recently, Kim et al. reported that mice feeding
either HFD or a high-fructose diet (HFrD) increased serum cholesterol, developed hepatic steatosis and
showed an enrichment in the Odoribacter, which produces butyrate. When both HFD and HFrD groups
were exposed to normal chow (NC), mice rescued only certain pathological features, such as lower
body weight, improved glucose tolerance and reduced fat accumulation in the liver. Interestingly,
Odoribacter remained enriched after NC and high levels of butyrate were correlated to persistent
changes in liver DNA methylation, probably due to butyrate ability to act as CpG islands modifier,
thus, suggesting a possible link between microbial by-products and nutriepigenomics [102,159].
Kimberly et al. had demonstrated that the composition of gut microbiota altered global histone
acetylation and methylation in host tissues in a diet-dependent manner. Mice fed a high-fat/high-sucrose
(HF/HS) diet, which contains low levels of fermentable complex polysaccharides, showed loss of cecal
SCFAs production (acetate, propionate and butyrate) compared to NC mice [160,161]. The reduction
of SCFAs correlated to profound post-translational modification of hepatic histones, such as lower
methylation of H3 histones in specific aminoacidic position (H3K27me1 and H3K36me2) [160,161].
The impact of unhealthy dietary habits on NAFLD and their interaction with inherited and acquired
risk factors is schematically represented in Figure 1.
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Bioactive compounds contained in food actively contribute to physical welfare and could
provide benefits as preventive and healing molecules for metabolic disorders, such as obesity, T2D
and NAFLD. Conversely, unhealthy dietary habits could affect metabolic homeostasis acting at
multiple levels. Chronic exposure to high fat/carbohydrate diets could increase intestinal barrier
permeability, favor dysbiosis and raise the amount of circulating bacterial endotoxins, thus, unbalancing
gut-liver axis bidirectional flux of metabolites. Interestingly, several micro/macro-nutrients may
specifically enrich certain bacterial species, such as Odoribacter, which are involved in changes of the
hepatic epigenetic landscape. In the liver, the presence of genetic variants predisposing to NAFLD
development and progression (I148M PNPLA3, E167K TM6SF2, the rs641738 in MBOAT7 gene, the
P446L GCKR and others) may alter the effectiveness of beneficial nutrients or accelerate the effects of
unhealthy by-products derived from junk food. Similarly, epigenetic modifiers (DNA methylation,
histone modifications and miRNAs regulation) could be highly nutrient-sensing, as they respond
to environmental cues and could establish long-lasting effects from the gestational and post-natal
period onward. The high complex network made by the combination of the environment, genes
and epigenetics may cause aberrant downstream responses to nutrients, determining NAFLD onset
and progression.
6. Precision and Accuracy: The Dartboard of Nutrition
If on the one hand junk food and a sedentary lifestyle cause metabolic dysfunction, on the
other hand, the study of nutri-genetics/epigenetics enabled us to identify either different genetic
polymorphisms, which may modulate the effectiveness of nutrients, and epigenetic markers that may
be potential therapeutic targets of specific dietary interventions. Livingstone et al. investigated the
effects of personalized nutrition in a European randomized controlled trial (Food4Me) (NCT01530139).
Among the 1607 participants, 448 were overweight and the internet-based personalized diet favored the
reduction of body weight and influenced dietary changes by enhancing the consumption of vegetarian
diet [162].
Bioactive substances, such as polyphenols, flavonoids, fish-derived oils and, in general, compounds
enriched in the MedDiet, predominantly consisting of fruits and vegetables, have shown systemic
benefits as preventive and curative molecules for metabolic diseases, cardiovascular risk and
cancer [163–166]. Regular intake of MedDiet with coenzyme Q10 (Med + CoQ diet) has been associated
with a lower expression of genes involved in inflammation, ER/oxidative stress and DNA damage in
the peripheral blood mononuclear cells (PMBCs) of 63 volunteers [166]. Yubero-Serrano et al. enrolled
20 individuals who were randomized to receive Med + CoQ for 4 weeks. They found that Med + CoQ
protects against ROS overproduction through mitigating the expression of oxidative, inflammatory and
fibrotic markers, such as superoxide dismutase (SOD) 1/2 and matrix metalloproteinase (MMP) 9 [165].
Interestingly, either bariatric surgery or energetic restriction through MedDiet, used as obesity treatment,
may also epigenetically modulate the expression of some of these markers influencing global DNA
methylation and hydroxymethylation [164,167]. A high-protein diet improved hepatic steatosis in a
mouse model of NAFLD independently of high fat and carbohydrate intake by increasing the lipid
and branched-chain amino acid (BCAA) catabolism, enhancing mitochondrial oxidative ability and
reducing fatty acid desaturation, ER stress and unfolded protein response [168]. α-lipoic acid (ALA),
a potent endogenous antioxidant and anti-inflammatory factor, has been shown to improve insulin
sensitivity and fatty liver in 50 NAFLD subjects enrolled in a double-blinded controlled trial [169].
In addition, ALA administration blocks hepatic TGFβ mediators, stimulates MMP13 activity and
actively participates to mitochondrial turnover inhibiting HDCA6, thus preventing hepatic damage and
fibrosis [170,171]. The supplementation of n-3 fatty acids has been observed to accelerate TG clearance
by augmenting the transcription rate of the PPARα-induced lipoprotein lipase activity (LPL) and
maternal n-3 administration may influence the predisposition of IR and T2D of the offspring [172,173].
However, the occurrence of the PPARα L162V polymorphism hampers n-3 beneficial effects both in
HepG2 cells and humans [172].
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Apple polyphenols and red wine extracts as resveratrol and derivates have been
shown to epigenetically prevent diet-induced obesity and ameliorate liver injury and cardiac
dysfunction [174–177]. For instance, curcumin acts as a free radical scavenger and hampers lipid
peroxidation and oxidative DNA damage. In a randomized double-blind placebo-controlled trial, the
short-term curcumin administration in NAFLD patients improved hepatic fat content and metabolic
profile (trial registration IRCT20100524004010N24) [178]. In addition, it has been demonstrated that
curcumin works as an HAT inhibitor specifically targeting p300/CREB-binding proteins [176] and
reduces the expression of DMT1 and pro-fibrotic markers (α smooth muscle actin (αSMA), Col1α1) in
rodents affected by carbon tetrachloride (CCL4)-induced liver fibrosis, thus exerting hepatoprotective
effects on fibrogenic processes [177]. Green tea, rich in polyphenols and catechins, is a natural
hypolipidemic, antioxidant and thermogenic agent whose beneficial effects on hepatic steatosis and
liver damage have been widely studied in both genetically and dietary induced experimental models
of NAFLD/NASH [179–185]. One of the mechanisms by which green tea protects against NAFLD is
linked to miR-34a and miR-194 downregulation accompanied by an increase in their mRNA targets,
such as Sirt1 and Pparα [186].
Nutri-Genetics/Epigenetics: A Smart Use of Nutrients in Ongoing Trials
According to the current knowledge that several nutrients could provide healing effects or rescue
some of the pathological features of the MetS, some clinical trials have been conducted to explore
gene-diet interactions as a plausible strategy to manage NAFLD/NASH. An observational study is
recruiting participants affected by obesity, diabetes, NAFLD and other metabolic diseases to evaluate
the effects of folates and the epigenetic mechanisms on severe obesity-related complications pre-
and post-bariatric surgical interventions (NCT02663388; OBESEPI). In a randomized-controlled trial
(NCT03183193) overweight NAFLD patients will receive FLiO diet, based on the distribution of
macronutrients as follows: 30%–35% lipid (extra virgin olive oil and fatty acids Ω3), 25% vegetable
proteins and 40%–45% fibers. As goals of this project, anthropometric and clinical outcomes will
be evaluated as well as gut microbiota composition and epigenetic changes in terms of DNA
methylation and miRNAs signature will be assessed to identify non-invasive biomarkers for early
diagnosis in obese individuals. Many bioactive substances in fruits, vegetables and plants have
antioxidant, anti-inflammatory, antimicrobial and lipid-lowering properties. Mastiha, a Greek
liqueur made with mastic resin, is under investigation in a multicenter, randomized, double-blind,
placebo-controlled trial (NCT03135873), named MAST4HEALTH. This study aims to assess the
effect of Mastiha supplementation on the clinical course of NAFLD/NASH patients and correlating
genetic/epigenetic markers with metabolomic and intestinal microbiota profiles. Interestingly, obese
adults with dyslipidemia and obese children with IR will be recruited in the NutriGen project
(NCT02837367). In this randomized triple-blind study, a nutrigenomic model will be exploited
to determine the effectiveness of treatments with specific dietary foods (supplements containing
methyl-donors), based on the genetic risk predisposition (genetic signature) of obese individuals.
A schematic description of the main clinical trials described in the present review is represented in
Table 1.
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Table 1. Clinical Trials Addressing Nutrigenomic Interventions in NAFLD Patients.
Clinical Trial
Start-End Date Status Study Type Interventions Conditions Objectives Locations
NCT00760513
11/09-11/18
Completed
(n = 103)
Interventional
Randomized
Phase IV
Omega-3-acid (OMACOR) 4
gr/d oral capsule for 18
months versus placebo
Biopsy-verified NASH or
Ultrasound-verified
NAFLD
Identify the effects of n-3 fatty
acids on fibrosis and
cardiovascular risk biomarkers
in NAFLD patients
Southampton General Hospital
Southampton, Hants, United
Kingdom
NCT00885313
03/09–03/11
Completed
(n = 60)
Interventional
Randomized
Phase II
DHA 250 or 500mg/kg/d oral
for 24 months vs. placebo
NAFLD and obesity in
children
Evaluate the effects of DHA on
Children With NAFLD
Bambino Gesù Hospital and
Research Institute Rome, Italy
NCT00697580
05/059–06/07
Completed
(n = 104)
Interventional
Randomized
Behavioral: Nutrition
changes and physical exercise
NAFLD and obesity in
adolescents
Investigate the Intra-Abdominal
Fat, insulin sensitivity and Risk
of Disease in Adolescents
Veronica Atkins Lifestyle
Intervention Laboratory Los
Angeles, CA (USA)
NCT00072995
09/03–09/07
Completed
(n = 811)
Interventional Four Diets Differing inMacronutrient Composition
and Low in Saturated Fat
Cardiovascular disease,
NAFLD, obesity
Preventing Obesity Using Novel
Dietary Strategies
Pennington Biomedical Research
Center, Louisiana State
University, Baton Rouge, LA
(USA). Harvard University
School of Public Health, Boston,
MA (USA)
NCT01530139
02/12–02/16
Completed
(n = 1607)
Interventional
Randomized
Three personalized diets
(Food4Me) versus control
diet
Adult individuals
Personalization of dietary
advices based on biochemical
and/or genetic information
Universities of Newcastle;
College Dublin; Maastricht; Oslo;
Navarra; Harokopio; Reading;
München; Newcastle Upon-Tyne
and National Food and Nutrition
Institute
NCT02663388
01/16–12/19
Recruiting
(n = 20,000) * Observational
Gastric bypass, sleeve, gastric
banding
Cardiovascular disease,
NAFLD, obesity, MetS,
T2D
Evaluate DNA Methylation on
severe obesity-related
complications before and after
bariatric surgery
University of Lorraine, CHU
Nancy
Vandoeuvre Les Nancy, France
NCT03183193
06/16–12/19
Recruiting
(n = 120) *
Interventional
Randomized FLiO diet versus control diet NAFLD and obesity
Nutritional/lifestyle
interventions to identify
non-invasive biomarkers to early
diagnosis of NAFLD in future
obese people
Centre for Nutrition Research,
University of Navarra Pamplona,
Navarra, Spain
NCT03135873
03/17–12/19
Recruiting
(n = 52) *
Interventional
Randomized
(Phase I)
Mastiha vs. placebo Obese NAFLD
Explore gene-diet interactions
and correlate genetic/epigenetic
markers with metabolome and
gut microbiota
Harokopio University, Athens,
Attica, Greece
NCT02837367
06/19–12/19
Recruiting
(n = 600) *
Interventional
Randomized
Administration of
supplements containing
methyl-donors
Obesity and dyslipidemia
Explore the genetic signature
involved in the donation of
methyl groups and unsaturated
omega-6/3 fatty acid metabolism
Clinica II Pediatrie Bega
Timisoara, Timis, Romania.
Spitalul Judetean Timisoara;
Centrul de Diabet Timisoara,
Timis, Romania
* Estimated number of participants.
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7. Concluding Remarks
The Western human diet has evolutionally changed, and nowadays, it is markedly enriched
in saturated and trans-fat, omega-6 fatty acids, carbohydrates and high-energy nutrients against
fruits, vegetables, proteins and omega-3 fatty acids [14]. Nutritional genomics address to study the
gene-environment interactions and the detrimental effect of the changes in our dietary landscape.
It may represent a promising tool to revolutionize both clinical and public health nutrition
practice and may favor the establishment of genome-informed nutrient and food-based dietary
guidelines for disease prevention and a healthy lifestyle, individualized medical nutrition therapy
for NAFLD management and better targeted health nutrition interventions, including micronutrient
supplementation, maximizing the benefits and in turn minimizing the adverse outcomes within
genetically diverse human populations [13]. In this context, the study of nutri-epigenetics is becoming
increasingly attractive, as it would allow to identify novel appealing bioactive compounds, which
may contribute specifically to modulate the hepatic epigenetic signature from maternal and lactation
period onward.
To date, no therapeutic strategy is approved for the treatment of NAFLD, and lifestyle modifications,
physical exercise and weight loss remain the cornerstone of approaches to patients with NAFLD.
Indeed, personalized nutritional recommendations for NAFLD patients remain largely unexplored
and the deep understanding of the mechanisms behind gene–environment interactions should be a
priority for future researches. Considering nutrigenomics as an option will guarantee us the clef to
compose the harmonic combination of nutrients suitable for our genome, orchestrating the perfect
symphony of the health.
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Abbreviations
5mC 5-methylcytosine
αSMA α smooth muscle actin
ACDRP Amish Complex Disease Research Program
ACLY ATP citrate lyase
ALA α-lipoic acid
ALT Alanine Aminotransferase
APO C3 Apolipoprotein C3
APOE Apolipoprotein E
b3AR Adrenergic receptor
BCAA Branched-Chain Amino Acid
BPA Bisphenol A
CASP1 Caspase 1
CBMN Cytokinesis-block micronucleus assay
CCL4 Carbon Tetrachloride
Cdkn1a Cyclin Dependent Kinase Inhibitor 1A
ChDD Choline-deficient diet
Col1A1 Collagen Type I α1
CPT1A Carnitine Palmitoyltransferase 1A
CRISPR/Cas9 Clustered regularly interspaced short palindromic repeats
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Cyp7A1 Cholesterol 7-α hydroxylase 1
DHA Docosahexaenoic acid
DNL De novo lipogenesis
DNMTs DNA methyltransferases
ELISA Enzyme-linked immunosorbent assay
ER Endothelial Reticulum
EPA Eicosapentanoic acid
EZH2 Enhancer of Zeste Homolog 2
FASN Fatty acid synthetase
FATP1 Fatty acid transporter 1
FA Fatty Acid
FFA Free Fatty Acid
FGF19 Fibroblast Growth Factor 19
FGFR2 Fibroblast growth factor receptor 2
FOXO1 Forkhead box O1
GCKR Glucokinase Regulatory Protein
GIFT Genetically Improved Farmed Tilapia
GSTM1 Glutathione S-transferase Mu 1
GSTT1 Glutathione S-transferase theta 1
GWAS Genome-wide association study
H3K9 Lysine 9 acetylation of histone H3
H3K36 Lysine 36 acetylation of histone H3
H3Me2K4 Lysine 4 dimethylation at histone H3
HAT Histone acetyltransferase
HCC Hepatocellular Carcinoma
HDAC8 Histone Deacetylase 8
HFD High Fat Diet
HFrD high-fructose diet
HF/HS High-Fat/High-Sucrose
HFS High Fat Sucrose
HSCs Hepatic Stellate Cells
HSD11B 11β-hydroxysteroid dehydrogenase
iPOP Integrated personal omic profile
IR Insulin Resistance
IUGR Intrauterine Grow Restriction
JHDM2A Jumonji C (JmjC)-Domain-containing Histone Demethylase 2A
LDL Low-density lipoprotein
LKB1/AMPK Liver Kinase B1/AMP-activated Protein Kinase
LP Low protein
LPIAT1 Lyso-phosphatidylinositol acyl-transferase1
LPL Lipoprotein lipase activity
LPS Lipopolysaccharides
LXRα Liver X receptor alpha
Lyso-PI Lyso-phosphatidylinositol
MAM Mitochondria-associated membrane
MBOAT7 Membrane Bound O-acyltransferase Domain-containing 7
MCD Methionine-Choline Deficient diet
MedDiet Mediterranean diet
MetS Metabolic Syndrome
miRNAs microRNAs
MMP Matrix Metalloproteinase
mtDNA Mitochondrial DNA
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MTHFR Methylenetetrahydrofolate reductase
MT-ND6 Mitochondrially encoded NADH dehydrogenase 6
MTTP Microsomal triglyceride transfer protein
MUFA Monounsaturated fatty acid
Myd88 Myeloid differentiation factor 88
NAFLD Nonalcoholic Fatty Liver Disease
NAS NAFLD activity score
NASH Nonalcoholic Steatohepatitis
NC Normal Chow
NF-κB Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
NIOR Nutrient-induced insulin output ratio
NMR Nuclear Magnetic Resonance
PA Palmitic acid
PCG1-α Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
PCSK7 Proprotein Convertase Subtilisin/Kexin Type 7
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9
PDGFα Platelet-derived growth factor alpha
PMBCs Peripheral blood mononuclear cells
PNPLA2 Patatin-like Phospholipase Domain Protein 2
PNPLA3 Patatin-like Phospholipase Domain Protein 3
PPARα Peroxisome proliferator-activated receptor α
PPARγ 2 Peroxisome proliferator-activated receptor γ2
PPP1R3B Protein Phosphatase 1 Regulatory subunit 3B
PUFA Polyunsaturated fatty acids
RNAseq RNA sequencing
ROS Reactive Oxygen Species
SAM S-adenyl methionine
SCD Stearoyl-CoA Desaturase
SCFAs Short Chain Fatty Acids
SFA Saturated fatty acid
Sirt Sirtuin
SNPs Single nucleotide polymorphisms
SOD Superoxide Dismutase
SREBP1c Sterol Regulatory Element Binding Protein 1c
SULT1A1 Sulfotransferase 1A1
T2D Type 2 Diabetes Mellitus
TA Tannic acid
TG Triglycerides
TGFβ1 Transforming growth factor β1
TLR4 Toll-like receptor 4
TM6SF2 Transmembrane 6 Superfamily Member 2
TMC4/MBOAT7 Transmembrane Channel-like 4/Membrane Bound O-acyltransferase Domain-containing
TNFα Tumor Necrosis Factor alpha
UCP-1 Uncoupling Protein type I
VLDL Very-low density lipoprotein
WNT Wingless-related integration site
References
1. Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of
nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology
2016, 64, 73–84. [CrossRef]
2. Day, C.P. From fat to inflammation. Gastroenterology 2006, 130, 207–210. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 23 of 32
3. Wong, R.J.; Aguilar, M.; Cheung, R.; Perumpail, R.B.; Harrison, S.A.; Younossi, Z.M.; Ahmed, A. Nonalcoholic
steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in
the United States. Gastroenterology 2015, 148, 547–555. [CrossRef]
4. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Bugianesi, E.; Lenzi, M.; McCullough, A.J.; Natale, S.;
Forlani, G.; Melchionda, N. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes
2001, 50, 1844–1850. [CrossRef]
5. Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol. 2015, 62 (Suppl. 1), S47–S64. [CrossRef]
6. Dongiovanni, P.; Valenti, L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci.
2017, 18, 1534. [CrossRef]
7. Dongiovanni, P.; Valenti, L. Genetics of nonalcoholic fatty liver disease. Metab. Clin. Exp. 2016, 65, 1026–1037.
[CrossRef] [PubMed]
8. Meroni, M.; Longo, M.; Erconi, V.; Valenti, L.; Gatti, S.; Fracanzani, A.L.; Dongiovanni, P. mir-101-3p
Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During
Insulin Resistance. Nutrients 2019, 11, 2597. [CrossRef] [PubMed]
9. Dongiovanni, P.; Meroni, M.; Longo, M.; Fargion, S.; Fracanzani, A.L. miRNA Signature in NAFLD: A Turning
Point for a Non-Invasive Diagnosis. Int. J. Mol. Sci. 2018, 19, 3966. [CrossRef] [PubMed]
10. Meroni, M.; Longo, M.; Dongiovanni, P. Alcohol or Gut Microbiota: Who Is the Guilty? Int. J. Mol. Sci. 2019,
20, 4568. [CrossRef]
11. Meroni, M.; Longo, M.; Dongiovanni, P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New
Insight into Therapeutic Strategies. Nutrients 2019, 11, 2642. [CrossRef] [PubMed]
12. Hesketh, J. Personalised nutrition: How far has nutrigenomics progressed? Eur. J. Clin. Nutr. 2013, 67,
430–435. [CrossRef]
13. Stover, P.J.; Caudill, M.A. Genetic and epigenetic contributions to human nutrition and health: Managing
genome-diet interactions. J. Am. Diet. Assoc. 2008, 108, 1480–1487. [CrossRef] [PubMed]
14. Kang, J.X. The coming of age of nutrigenetics and nutrigenomics. J. Nutr. Nutr. 2012, 5, I-II. [CrossRef]
[PubMed]
15. Arigony, A.L.; de Oliveira, I.M.; Machado, M.; Bordin, D.L.; Bergter, L.; Pra, D.; Henriques, J.A. The influence
of micronutrients in cell culture: A reflection on viability and genomic stability. Biomed Res. Int. 2013, 2013,
597282. [CrossRef] [PubMed]
16. Fenech, M. Genome health nutrigenomics and nutrigenetics–diagnosis and nutritional treatment of genome
damage on an individual basis. Food Chem. Toxicol. 2008, 46, 1365–1370. [CrossRef] [PubMed]
17. Fenech, M.; Baghurst, P.; Luderer, W.; Turner, J.; Record, S.; Ceppi, M.; Bonassi, S. Low intake of calcium,
folate, nicotinic acid, vitamin E, retinol, beta-carotene and high intake of pantothenic acid, biotin and
riboflavin are significantly associated with increased genome instability–results from a dietary intake and
micronucleus index survey in South Australia. Carcinogenesis 2005, 26, 991–999. [CrossRef] [PubMed]
18. Nakajima, T.; Moriguchi, M.; Katagishi, T.; Sekoguchi, S.; Nishikawa, T.; Takashima, H.; Kimura, H.;
Minami, M.; Itoh, Y.; Kagawa, K.; et al. Premature telomere shortening and impaired regenerative response
in hepatocytes of individuals with NAFLD. Liver Int. 2006, 26, 23–31. [CrossRef]
19. Ferguson, L.R.; De Caterina, R.; Görman, U.; Allayee, H.; Kohlmeier, M.; Prasad, C.; Choi, M.S.; Curi, R.; de
Luis, D.A.; Gil, A.; et al. Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on
Personalised Nutrition: Part 1—Fields of Precision Nutrition. Lifestyle Genom. 2016, 9, 12–27. [CrossRef]
[PubMed]
20. Stover, P.J. Physiology of folate and vitamin B12 in health and disease. Nutr. Rev. 2004, 62, S3–S12. [CrossRef]
[PubMed]
21. Christensen, B.; Arbour, L.; Tran, P.; Leclerc, D.; Sabbaghian, N.; Platt, R.; Gilfix, B.M.; Rosenblatt, D.S.;
Gravel, R.A.; Forbes, P.; et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine
synthase, folate levels in red blood cells, and risk of neural tube defects. Am. J. Med Genet. 1999, 84, 151–157.
[CrossRef]
22. Sun, M.Y.; Zhang, L.; Shi, S.L.; Lin, J.N. Associations between Methylenetetrahydrofolate Reductase (MTHFR)
Polymorphisms and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: A Meta-Analysis. PLoS ONE 2016,
11, e0154337. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 2986 24 of 32
23. Ma, J.; Stampfer, M.J.; Giovannucci, E.; Artigas, C.; Hunter, D.J.; Fuchs, C.; Willett, W.C.; Selhub, J.;
Hennekens, C.H.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and
risk of colorectal cancer. Cancer Res. 1997, 57, 1098–1102. [PubMed]
24. Esfahani, S.T.; Cogger, E.A.; Caudill, M.A. Heterogeneity in the prevalence of methylenetetrahydrofolate
reductase gene polymorphisms in women of different ethnic groups. J. Am. Diet. Assoc. 2003, 103, 200–207.
[CrossRef]
25. Toomajian, C.; Ajioka, R.S.; Jorde, L.B.; Kushner, J.P.; Kreitman, M. A method for detecting recent selection in
the human genome from allele age estimates. Genetics 2003, 165, 287–297.
26. Brennan, L.; McNulty, B. New technology in nutrition research and practice. Proc. Nutr. Soc. 2017, 76,
173–174. [CrossRef]
27. Müller, M.; Kersten, S. Nutrigenomics: Goals and strategies. Nat. Rev. Genet. 2003, 4, 315–322. [CrossRef]
28. Neeha, V.S.; Kinth, P. Nutrigenomics research: A review. J. Food Sci. Technol. 2013, 50, 415–428. [CrossRef]
29. Roche, H.M. Nutrigenomics—New approaches for human nutrition research. J. Sci. Food Agric. 2006, 86,
1156–1163. [CrossRef]
30. Pico, C.; Serra, F.; Rodriguez, A.M.; Keijer, J.; Palou, A. Biomarkers of Nutrition and Health: New Tools for
New Approaches. Nutrients 2019, 11, 1092. [CrossRef]
31. Xie, S.; Moya, C.; Bilgin, B.; Jayaraman, A.; Walton, S.P. Emerging affinity-based techniques in proteomics.
Expert Rev. Proteom. 2009, 6, 573–583. [CrossRef] [PubMed]
32. Wang, J.; Li, D.; Dangott, L.J.; Wu, G. Proteomics and Its Role in Nutrition Research. J. Nutr. 2006, 136,
1759–1762. [CrossRef] [PubMed]
33. Chirita-Emandi, A.; Niculescu, M. Chapter 7—Methods for Global Nutrigenomics and Precision Nutrition.
In Principles of Nutrigenetics and Nutrigenomics; Caterina, R.D.E., Martinez, J.A., Kohlmeier, M., Eds.; Academic
Press: Cambridge, MA, USA, 2020; pp. 49–58. [CrossRef]
34. Xie, Z.; Li, H.; Wang, K.; Lin, J.; Wang, Q.; Zhao, G.; Jia, W.; Zhang, Q. Analysis of transcriptome and
metabolome profiles alterations in fatty liver induced by high-fat diet in rat. Metab. Clin. Exp. 2010, 59,
554–560. [CrossRef] [PubMed]
35. Chen, R.; Mias, G.I.; Li-Pook-Than, J.; Jiang, L.; Lam, H.Y.; Chen, R.; Miriami, E.; Karczewski, K.J.;
Hariharan, M.; Dewey, F.E.; et al. Personal omics profiling reveals dynamic molecular and medical
phenotypes. Cell 2012, 148, 1293–1307. [CrossRef] [PubMed]
36. Dongiovanni, P.; Anstee, Q.M.; Valenti, L. Genetic predisposition in NAFLD and NASH: Impact on severity
of liver disease and response to treatment. Curr. Pharm. Des. 2013, 19, 5219–5238. [CrossRef]
37. Dongiovanni, P.; Romeo, S.; Valenti, L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and
Steatohepatitis. Biomed Res. Int. 2015, 2015, 460190. [CrossRef]
38. Schwimmer, J.B.; Celedon, M.A.; Lavine, J.E.; Salem, R.; Campbell, N.; Schork, N.J.; Shiehmorteza, M.;
Yokoo, T.; Chavez, A.; Middleton, M.S.; et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology
2009, 136, 1585–1592. [CrossRef]
39. Willner, I.R.; Waters, B.; Patil, S.R.; Reuben, A.; Morelli, J.; Riely, C.A. Ninety patients with nonalcoholic
steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am. J. Gastroenterol. 2001, 96,
2957–2961. [CrossRef]
40. Guerrero, R.; Vega, G.L.; Grundy, S.M.; Browning, J.D. Ethnic differences in hepatic steatosis: An insulin
resistance paradox? Hepatology 2009, 49, 791–801. [CrossRef]
41. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.A.; Boerwinkle, E.; Cohen, J.C.;
Hobbs, H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat.
Genet. 2008, 40, 1461–1465. [CrossRef]
42. Pingitore, P.; Dongiovanni, P.; Motta, B.M.; Meroni, M.; Lepore, S.M.; Mancina, R.M.; Pelusi, S.; Russo, C.;
Caddeo, A.; Rossi, G.; et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis.
Hum. Mol. Genet. 2016, 25, 5212–5222. [CrossRef] [PubMed]
43. Mondul, A.; Mancina, R.M.; Merlo, A.; Dongiovanni, P.; Rametta, R.; Montalcini, T.; Valenti, L.; Albanes, D.;
Romeo, S. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver
Disease or Obesity. J. Nutr. 2015, 145, 1687–1691. [CrossRef] [PubMed]
44. Dongiovanni, P.; Romeo, S.; Valenti, L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of
environmental and genetic factors. World J. Gastroenterol. 2014, 20, 12945–12955. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 2986 25 of 32
45. BasuRay, S.; Smagris, E.; Cohen, J.C.; Hobbs, H.H. The PNPLA3 variant associated with fatty liver disease
(I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 2017, 66, 1111–1124. [CrossRef]
[PubMed]
46. Donati, B.; Motta, B.M.; Pingitore, P.; Meroni, M.; Pietrelli, A.; Alisi, A.; Petta, S.; Xing, C.; Dongiovanni, P.;
del Menico, B.; et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing
3 expression and liver damage. Hepatology 2016, 63, 787–798. [CrossRef]
47. Li, J.Z.; Huang, Y.; Karaman, R.; Ivanova, P.T.; Brown, H.A.; Roddy, T.; Castro-Perez, J.; Cohen, J.C.;
Hobbs, H.H. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin.
Investig. 2012, 122, 4130–4144. [CrossRef] [PubMed]
48. Dongiovanni, P.; Donati, B.; Fares, R.; Lombardi, R.; Mancina, R.M.; Romeo, S.; Valenti, L. PNPLA3 I148M
polymorphism and progressive liver disease. World J. Gastroenterol. 2013, 19, 6969–6978. [CrossRef]
49. Valenti, L.; Motta, B.M.; Soardo, G.; Iavarone, M.; Donati, B.; Sangiovanni, A.; Carnelutti, A.; Dongiovanni, P.;
Rametta, R.; Bertelli, C.; et al. PNPLA3 I148M polymorphism, clinical presentation, and survival in patients
with hepatocellular carcinoma. PLoS ONE 2013, 8, e75982. [CrossRef]
50. Pirazzi, C.; Valenti, L.; Motta, B.M.; Pingitore, P.; Hedfalk, K.; Mancina, R.M.; Burza, M.A.; Indiveri, C.;
Ferro, Y.; Montalcini, T.; et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
Hum. Mol. Genet. 2014, 23, 4077–4085. [CrossRef]
51. Huang, Y.; He, S.; Li, J.Z.; Seo, Y.-K.; Osborne, T.F.; Cohen, J.C.; Hobbs, H.H. A feed-forward loop amplifies
nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. USA 2010, 107, 7892–7897. [CrossRef]
52. Baulande, S.; Lasnier, F.; Lucas, M.; Pairault, J. Adiponutrin, a transmembrane protein corresponding to a
novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J. Biol. Chem. 2001,
276, 33336–33344. [CrossRef]
53. Santoro, N.; Savoye, M.; Kim, G.; Marotto, K.; Shaw, M.M.; Pierpont, B.; Caprio, S. Hepatic fat accumulation
is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary
omega6/omega3 PUFA intake. PLoS ONE 2012, 7, e37827. [CrossRef] [PubMed]
54. Huang, Y.; Cohen, J.C.; Hobbs, H.H. Expression and characterization of a PNPLA3 protein isoform (I148M)
associated with nonalcoholic fatty liver disease. J. Biol. Chem. 2011, 286, 37085–37093. [CrossRef]
55. Simopoulos, A.P. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other
chronic diseases. Exp. Biol. Med. 2008, 233, 674–688. [CrossRef]
56. Perttilä, J.; Huaman-Samanez, C.; Caron, S.; Tanhuanpää, K.; Staels, B.; Yki-Järvinen, H.; Olkkonen, V.M.
PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride
hydrolysis. Am. J. Physiol. Endocrinol. Metab. 2012, 302, E1063–E1069. [CrossRef]
57. Scorletti, E.; West, A.L.; Bhatia, L.; Hoile, S.P.; McCormick, K.G.; Burdge, G.C.; Lillycrop, K.A.; Clough, G.F.;
Calder, P.C.; Byrne, C.D. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and
TM6SF2 genotypes: Results from the WELCOME trial. J. Hepatol. 2015, 63, 1476–1483. [CrossRef]
58. Nobili, V.; Bedogni, G.; Donati, B.; Alisi, A.; Valenti, L. The I148M variant of PNPLA3 reduces the response
to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J. Med. Food 2013, 16, 957–960.
[CrossRef]
59. Mancina, R.M.; Matikainen, N.; Maglio, C.; Söderlund, S.; Lundbom, N.; Hakkarainen, A.; Rametta, R.;
Mozzi, E.; Fargion, S.; Valenti, L.; et al. Paradoxical dissociation between hepatic fat content and de novo
lipogenesis due to PNPLA3 sequence variant. J. Clin. Endocrinol. Metab. 2015, 100, E821–E825. [CrossRef]
60. Davis, J.N.; Lê, K.-A.; Walker, R.W.; Vikman, S.; Spruijt-Metz, D.; Weigensberg, M.J.; Allayee, H.; Goran, M.I.
Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in
PNPLA3 and high dietary carbohydrate and sugar consumption. Am. J. Clin. Nutr. 2010, 92, 1522–1527.
[CrossRef]
61. Sevastianova, K.; Kotronen, A.; Gastaldelli, A.; Perttilä, J.; Hakkarainen, A.; Lundbom, J.; Suojanen, L.;
Orho-Melander, M.; Lundbom, N.; Ferrannini, E.; et al. Genetic variation in PNPLA3 (adiponutrin) confers
sensitivity to weight loss-induced decrease in liver fat in humans. Am. J. Clin. Nutr. 2011, 94, 104–111.
[CrossRef]
62. Nobili, V.; Liccardo, D.; Bedogni, G.; Salvatori, G.; Gnani, D.; Bersani, I.; Alisi, A.; Valenti, L.; Raponi, M.
Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents.
Genes Nutr. 2014, 9, 392. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 2986 26 of 32
63. Marzuillo, P.; Grandone, A.; Perrone, L.; del Giudice, E.M. Weight loss allows the dissection of the interaction
between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J. Hepatol. 2013, 59,
1143–1144. [CrossRef]
64. Kozlitina, J.; Smagris, E.; Stender, S.; Nordestgaard, B.G.; Zhou, H.H.; Tybjærg-Hansen, A.; Vogt, T.F.;
Hobbs, H.H.; Cohen, J.C. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility
to nonalcoholic fatty liver disease. Nat. Genet. 2014, 46, 352–356. [CrossRef]
65. Luukkonen, P.K.; Zhou, Y.; Nidhina Haridas, P.A.; Dwivedi, O.P.; Hyötyläinen, T.; Ali, A.; Juuti, A.;
Leivonen, M.; Tukiainen, T.; Ahonen, L.; et al. Impaired hepatic lipid synthesis from polyunsaturated fatty
acids in TM6SF2 E167K variant carriers with NAFLD. J. Hepatol. 2017, 67, 128–136. [CrossRef]
66. Dongiovanni, P.; Petta, S.; Maglio, C.; Fracanzani, A.L.; Pipitone, R.; Mozzi, E.; Motta, B.M.; Kaminska, D.;
Rametta, R.; Grimaudo, S.; et al. Transmembrane 6 superfamily member 2 gene variant disentangles
nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015, 61, 506–514. [CrossRef]
67. Goffredo, M.; Caprio, S.; Feldstein, A.E.; D’Adamo, E.; Shaw, M.M.; Pierpont, B.; Savoye, M.; Zhao, H.;
Bale, A.E.; Santoro, N. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver
disease: A multiethnic study. Hepatology 2016, 63, 117–125. [CrossRef] [PubMed]
68. Smagris, E.; Gilyard, S.; BasuRay, S.; Cohen, J.C.; Hobbs, H.H. Inactivation of Tm6sf2, a Gene Defective in
Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins. J. Biol. Chem.
2016, 291, 10659–10676. [CrossRef] [PubMed]
69. O’Hare, E.A.; Yang, R.; Yerges-Armstrong, L.M.; Sreenivasan, U.; McFarland, R.; Leitch, C.C.; Wilson, M.H.;
Narina, S.; Gorden, A.; Ryan, K.A.; et al. TM6SF2 rs58542926 impacts lipid processing in liver and small
intestine. Hepatology 2017, 65, 1526–1542. [CrossRef] [PubMed]
70. Musso, G.; Cipolla, U.; Cassader, M.; Pinach, S.; Saba, F.; De Michieli, F.; Paschetta, E.; Bongiovanni, D.;
Framarin, L.; Leone, N.; et al. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and
glucose homeostasis in NAFLD. J. Lipid Res. 2017, 58, 1221–1229. [CrossRef]
71. Krawczyk, M.; Stachowska, E.; Milkiewicz, P.; Lammert, F.; Milkiewicz, M. Reduction of Caloric Intake
Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients
with Fatty Liver: Ultrasound-Based Prospective Study. Digestion 2016, 93, 139–148. [CrossRef] [PubMed]
72. Dongiovanni, P.; Petta, S.; Mannisto, V.; Mancina, R.M.; Pipitone, R.; Karja, V.; Maggioni, M.; Kakela, P.;
Wiklund, O.; Mozzi, E.; et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol.
2015, 63, 705–712. [CrossRef] [PubMed]
73. Beer, N.L.; Tribble, N.D.; McCulloch, L.J.; Roos, C.; Johnson, P.R.; Orho-Melander, M.; Gloyn, A.L. The P446L
variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through
increased glucokinase activity in liver. Hum. Mol. Genet. 2009, 18, 4081–4088. [CrossRef] [PubMed]
74. Santoro, N.; Caprio, S.; Pierpont, B.; Van Name, M.; Savoye, M.; Parks, E.J. Hepatic De Novo Lipogenesis in
Obese Youth Is Modulated by a Common Variant in the GCKR Gene. J. Clin. Endocrinol. Metab. 2015, 100,
E1125–E1132. [CrossRef]
75. Valenti, L.; Alisi, A.; Nobili, V. Unraveling the genetics of fatty liver in obese children: Additive effect of
P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 2012, 55, 661–663. [CrossRef]
76. Kaliora, A.C.; Kalafati, I.P.; Gioxari, A.; Diolintzi, A.; Kokkinos, A.; Dedoussis, G.V. A modified response of
NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. Eur. J.
Nutr. 2018, 57, 2227–2235. [CrossRef]
77. Santoro, N.; Zhang, C.K.; Zhao, H.; Pakstis, A.J.; Kim, G.; Kursawe, R.; Dykas, D.J.; Bale, A.E.; Giannini, C.;
Pierpont, B.; et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in
obese children and adolescents. Hepatology 2012, 55, 781–789. [CrossRef]
78. Nettleton, J.A.; McKeown, N.M.; Kanoni, S.; Lemaitre, R.N.; Hivert, M.F.; Ngwa, J.; van Rooij, F.J.;
Sonestedt, E.; Wojczynski, M.K.; Ye, Z.; et al. Interactions of dietary whole-grain intake with fasting glucose-
and insulin-related genetic loci in individuals of European descent: A meta-analysis of 14 cohort studies.
Diabetes Care 2010, 33, 2684–2691. [CrossRef]
79. Sotos-Prieto, M.; Guillén, M.; Vicente Sorli, J.; Portolés, O.; Guillem-Saiz, P.; Ignacio Gonzalez, J.; Qi, L.;
Corella, D. Relevant associations of the glucokinase regulatory protein/glucokinase gene variation with TAG
concentrations in a high-cardiovascular risk population: Modulation by the Mediterranean diet. Br. J. Nutr.
2013, 109, 193–201. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 27 of 32
80. Lee, H.-J.; Jang, H.B.; Kim, H.-J.; Ahn, Y.; Hong, K.-W.; Cho, S.B.; Kang, J.H.; Park, S.I. The dietary
monounsaturated to saturated fatty acid ratio modulates the genetic effects of GCKR on serum lipid levels in
children. Clin. Chim. Acta Int. J. Clin. Chem. 2015, 450, 155–161. [CrossRef]
81. Buch, S.; Stickel, F.; Trépo, E.; Way, M.; Herrmann, A.; Nischalke, H.D.; Brosch, M.; Rosendahl, J.; Berg, T.;
Ridinger, M.; et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7
as risk loci for alcohol-related cirrhosis. Nat. Genet. 2015, 47, 1443–1448. [CrossRef]
82. Mancina, R.M.; Dongiovanni, P.; Petta, S.; Pingitore, P.; Meroni, M.; Rametta, R.; Boren, J.; Montalcini, T.;
Pujia, A.; Wiklund, O.; et al. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty
Liver Disease in Individuals of European Descent. Gastroenterology 2016, 150, 1219–1230. [CrossRef]
83. Donati, B.; Dongiovanni, P.; Romeo, S.; Meroni, M.; McCain, M.; Miele, L.; Petta, S.; Maier, S.; Rosso, C.; De
Luca, L.; et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci. Rep.
2017, 7, 4492. [CrossRef] [PubMed]
84. Thabet, K.; Chan, H.L.Y.; Petta, S.; Mangia, A.; Berg, T.; Boonstra, A.; Brouwer, W.P.; Abate, M.L.; Wong, V.W.;
Nazmy, M.; et al. The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases
inflammation and fibrosis in chronic hepatitis B. Hepatology 2017, 65, 1840–1850. [CrossRef]
85. Thabet, K.; Asimakopoulos, A.; Shojaei, M.; Romero-Gomez, M.; Mangia, A.; Irving, W.L.; Berg, T.; Dore, G.J.;
Gronbaek, H.; Sheridan, D.; et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to
fibrosis in chronic hepatitis C. Nat. Commun. 2016, 7, 12757. [CrossRef]
86. Zarini, S.; Hankin, J.A.; Murphy, R.C.; Gijon, M.A. Lysophospholipid acyltransferases and eicosanoid
biosynthesis in zebrafish myeloid cells. Prostaglandins Other Lipid Mediat. 2014, 113–115, 52–61. [CrossRef]
[PubMed]
87. Meroni, M.; Dongiovanni, P.; Longo, M.; Carli, F.; Baselli, G.; Rametta, R.; Pelusi, S.; Badiali, S.; Maggioni, M.;
Gaggini, M.; et al. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.
EBioMedicine 2020, 52, 102658. [CrossRef]
88. Miele, L.; Dall’armi, V.; Cefalo, C.; Nedovic, B.; Arzani, D.; Amore, R.; Rapaccini, G.; Gasbarrini, A.;
Ricciardi, W.; Grieco, A.; et al. A case-control study on the effect of metabolic gene polymorphisms, nutrition,
and their interaction on the risk of non-alcoholic fatty liver disease. Genes Nutr. 2014, 9, 383. [CrossRef]
89. Stachowska, E.; Ryterska, K.; Maciejewska, D.; Banaszczak, M.; Milkiewicz, P.; Milkiewicz, M.; Gutowska, I.;
Ossowski, P.; Kaczorowska, M.; Jamioł-Milc, D.; et al. Nutritional Strategies for the Individualized Treatment
of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR).
Int. J. Mol. Sci. 2016, 17, 1192. [CrossRef]
90. Dongiovanni, P.; Meroni, M.; Baselli, G.; Mancina, R.M.; Ruscica, M.; Longo, M.; Rametta, R.; Cespiati, A.;
Pelusi, S.; Ferri, N.; et al. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation
in NAFLD patients. J. Lipid Res. 2019, 60, 1144–1153. [CrossRef]
91. Huang, T.; Huang, J.; Qi, Q.; Li, Y.; Bray, G.A.; Rood, J.; Sacks, F.M.; Qi, L. PCSK7 genotype modifies effect of
a weight-loss diet on 2-year changes of insulin resistance: The POUNDS LOST trial. Diabetes Care 2015, 38,
439–444. [CrossRef]
92. Cohen, J.; Pertsemlidis, A.; Kotowski, I.K.; Graham, R.; Garcia, C.K.; Hobbs, H.H. Low LDL cholesterol in
individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 2005, 37,
161–165. [CrossRef] [PubMed]
93. Ruscica, M.; Ferri, N.; Macchi, C.; Meroni, M.; Lanti, C.; Ricci, C.; Maggioni, M.; Fracanzani, A.L.; Badiali, S.;
Fargion, S.; et al. Liver fat accumulation is associated with circulating PCSK9. Ann. Med. 2016, 48, 384–391.
[CrossRef]
94. Trinder, M.; Francis, G.A.; Brunham, L.R. Association of Monogenic vs Polygenic Hypercholesterolemia
With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2020. [CrossRef] [PubMed]
95. Costet, P.; Cariou, B.; Lambert, G.; Lalanne, F.; Lardeux, B.; Jarnoux, A.L.; Grefhorst, A.; Staels, B.; Krempf, M.
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding
protein 1c. J. Biol. Chem. 2006, 281, 6211–6218. [CrossRef]
96. Dongiovanni, P.; Meroni, M.; Mancina, R.M.; Baselli, G.; Rametta, R.; Pelusi, S.; Mannisto, V.; Fracanzani, A.L.;
Badiali, S.; Miele, L.; et al. Protein phosphatase 1 regulatory subunit 3B gene variation protects against
hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatol.
Commun. 2018, 2, 666–675. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 28 of 32
97. Stender, S.; Smagris, E.; Lauridsen, B.K.; Kofoed, K.F.; Nordestgaard, B.G.; Tybjaerg-Hansen, A.;
Pennacchio, L.A.; Dickel, D.E.; Cohen, J.C.; Hobbs, H.H. Relationship between genetic variation at PPP1R3B
and levels of liver glycogen and triglyceride. Hepatology 2018, 67, 2182–2195. [CrossRef]
98. Mehta, M.B.; Shewale, S.V.; Sequeira, R.N.; Millar, J.S.; Hand, N.J. Hepatic protein phosphatase 1 regulatory
subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis.
J. Biol. Chem. 2017, 292, 10444–10454. [CrossRef]
99. Remely, M.; Stefanska, B.; Lovrecic, L.; Magnet, U.; Haslberger, A.G. Nutriepigenomics: The role of nutrition
in epigenetic control of human diseases. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 328–333. [CrossRef]
100. Barker, D.J. Developmental origins of adult health and disease. J. Epidemiol. Community Health 2004, 58,
114–115. [CrossRef]
101. Goyal, R.; Goyal, D.; Leitzke, A.; Gheorghe, C.P.; Longo, L.D. Brain renin-angiotensin system: Fetal epigenetic
programming by maternal protein restriction during pregnancy. Reprod. Sci. 2010, 17, 227–238. [CrossRef]
102. Wankhade, U.D.; Zhong, Y.; Kang, P.; Alfaro, M.; Chintapalli, S.V.; Thakali, K.M.; Shankar, K. Enhanced
offspring predisposition to steatohepatitis with maternal high-fat diet is associated with epigenetic and
microbiome alterations. PLoS ONE 2017, 12, e0175675. [CrossRef]
103. Zhou, D.; Pan, Y.X. Pathophysiological basis for compromised health beyond generations: Role of maternal
high-fat diet and low-grade chronic inflammation. J. Nutr. Biochem. 2015, 26, 1–8. [CrossRef]
104. Murphy, S.K.; Yang, H.; Moylan, C.A.; Pang, H.; Dellinger, A.; Abdelmalek, M.F.; Garrett, M.E.;
Ashley-Koch, A.; Suzuki, A.; Tillmann, H.L.; et al. Relationship between methylome and transcriptome in
patients with nonalcoholic fatty liver disease. Gastroenterology 2013, 145, 1076–1087. [CrossRef]
105. Pirola, C.J.; Gianotti, T.F.; Burgueno, A.L.; Rey-Funes, M.; Loidl, C.F.; Mallardi, P.; Martino, J.S.; Castano, G.O.;
Sookoian, S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of
nonalcoholic fatty liver disease. Gut 2013, 62, 1356–1363. [CrossRef]
106. Moore, L.D.; Le, T.; Fan, G. DNA methylation and its basic function. Neuropsychopharmacol. Off. Publ. Am.
Coll. Neuropsychopharmacol. 2013, 38, 23–38. [CrossRef] [PubMed]
107. Cordero, P.; Milagro, F.I.; Campion, J.; Martinez, J.A. Maternal methyl donors supplementation during
lactation prevents the hyperhomocysteinemia induced by a high-fat-sucrose intake by dams. Int. J. Mol. Sci.
2013, 14, 24422–24437. [CrossRef]
108. Mikael, L.G.; Pancer, J.; Wu, Q.; Rozen, R. Disturbed one-carbon metabolism causing adverse reproductive
outcomes in mice is associated with altered expression of apolipoprotein AI and inflammatory mediators
PPARalpha, interferon-gamma, and interleukin-10. J. Nutr. 2012, 142, 411–418. [CrossRef] [PubMed]
109. Wang, L.J.; Zhang, H.W.; Zhou, J.Y.; Liu, Y.; Yang, Y.; Chen, X.L.; Zhu, C.H.; Zheng, R.D.; Ling, W.H.; Zhu, H.L.
Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic
methylation in mice fed a high-fat diet. J. Nutr. Biochem. 2014, 25, 329–336. [CrossRef] [PubMed]
110. Takaya, J.; Yamanouchi, S.; Kaneko, K. A Calcium-Deficient Diet in Rat Dams during Gestation and Nursing
Affects Hepatic 11β-hydroxysteroid dehydrogenase-1 Expression in the Offspring. PLoS ONE 2014, 9, e84125.
[CrossRef] [PubMed]
111. Takaya, J.; Iharada, A.; Okihana, H.; Kaneko, K. Magnesium deficiency in pregnant rats alters methylation of
specific cytosines in the hepatic hydroxysteroid dehydrogenase-2 promoter of the offspring. Epigenetics 2011,
6, 573–578. [CrossRef]
112. Dudley, K.J.; Sloboda, D.M.; Connor, K.L.; Beltrand, J.; Vickers, M.H. Offspring of mothers fed a high fat diet
display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation. PLoS
ONE 2011, 6, e21662. [CrossRef] [PubMed]
113. Pogribny, I.P.; Shpyleva, S.I.; Muskhelishvili, L.; Bagnyukova, T.V.; Jill James, S.; Beland, F.A. Role of DNA
damage and alterations in cytosine DNA methylation in rat liver carcinogenesis induced by a methyl-deficient
diet. Mutat. Res. Fundam. Mol. Mech. Mutagenesis 2009, 669, 56–62. [CrossRef] [PubMed]
114. Zeybel, M.; Hardy, T.; Robinson, S.M.; Fox, C.; Anstee, Q.M.; Ness, T.; Masson, S.; Mathers, J.C.; French, J.;
White, S.; et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty
liver disease and alcoholic liver disease. Clin. Epigenetics 2015, 7, 25. [CrossRef]
115. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 2011, 21, 381–395.
[CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 29 of 32
116. Inagaki, T.; Tachibana, M.; Magoori, K.; Kudo, H.; Tanaka, T.; Okamura, M.; Naito, M.; Kodama, T.; Shinkai, Y.;
Sakai, J. Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice. Genes Cells 2009,
14, 991–1001. [CrossRef]
117. Sohi, G.; Marchand, K.; Revesz, A.; Arany, E.; Hardy, D.B. Maternal protein restriction elevates cholesterol in
adult rat offspring due to repressive changes in histone modifications at the cholesterol 7alpha-hydroxylase
promoter. Mol. Endocrinol. 2011, 25, 785–798. [CrossRef]
118. Chang, H.C.; Guarente, L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 2014, 25,
138–145. [CrossRef]
119. Pazienza, V.; Borghesan, M.; Mazza, T.; Sheedfar, F.; Panebianco, C.; Williams, R.; Mazzoccoli, G.; Andriulli, A.;
Nakanishi, T.; Vinciguerra, M. SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against
lipid accumulation. Aging 2014, 6, 35–47. [CrossRef] [PubMed]
120. Lee, J.H.; Friso, S.; Choi, S.-W. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver
diseases and nutrition. Nutrients 2014, 6, 3303–3325. [CrossRef]
121. Hirschey, M.D.; Shimazu, T.; Jing, E.; Grueter, C.A.; Collins, A.M.; Aouizerat, B.; Stancakova, A.; Goetzman, E.;
Lam, M.M.; Schwer, B.; et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the
development of the metabolic syndrome. Mol. Cell 2011, 44, 177–190. [CrossRef]
122. Chung, M.Y.; Song, J.H.; Lee, J.; Shin, E.J.; Park, J.H.; Lee, S.H.; Hwang, J.T.; Choi, H.K. Tannic acid, a novel
histone acetyltransferase inhibitor, prevents non-alcoholic fatty liver disease both in vivo and in vitro model.
Mol. Metab. 2019, 19, 34–48. [CrossRef] [PubMed]
123. Tian, Y.; Wong, V.W.S.; Wong, G.L.H.; Yang, W.; Sun, H.; Shen, J.; Tong, J.H.M.; Go, M.Y.Y.; Cheung, Y.S.;
Lai, P.B.S.; et al. Histone Deacetylase HDAC8 Promotes Insulin Resistance and β-Catenin Activation in
NAFLD-Associated Hepatocellular Carcinoma. Cancer Res. 2015, 75, 4803–4816. [CrossRef] [PubMed]
124. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
125. Baffy, G. MicroRNAs in Nonalcoholic Fatty Liver Disease. J. Clin. Med. 2015, 4, 1977–1988. [CrossRef]
[PubMed]
126. Panera, N.; Gnani, D.; Crudele, A.; Ceccarelli, S.; Nobili, V.; Alisi, A. MicroRNAs as controlled systems and
controllers in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20, 15079–15086. [CrossRef]
127. Meroni, M.; Longo, M.; Rametta, R.; Dongiovanni, P. Genetic and Epigenetic Modifiers of Alcoholic Liver
Disease. Int. J. Mol. Sci. 2018, 19, 3857. [CrossRef]
128. Del Campo, J.A.; Gallego-Durán, R.; Gallego, P.; Grande, L. Genetic and Epigenetic Regulation in Nonalcoholic
Fatty Liver Disease (NAFLD). Int. J. Mol. Sci. 2018, 19, 911. [CrossRef]
129. Thomas, M.; Deiters, A. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules.
Curr. Med. Chem. 2013, 20, 3629–3640. [CrossRef]
130. Qiang, J.; Tao, Y.F.; Bao, J.W.; Chen, D.J.; Li, H.X.; He, J.; Xu, P. High Fat Diet-Induced miR-122 Regulates
Lipid Metabolism and Fat Deposition in Genetically Improved Farmed Tilapia (GIFT, Oreochromis niloticus)
Liver. Front. Physiol. 2018, 9. [CrossRef]
131. Long, J.-K.; Dai, W.; Zheng, Y.-W.; Zhao, S.-P. miR-122 promotes hepatic lipogenesis via inhibiting the
LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol. Med. 2019, 25, 26.
[CrossRef]
132. Ding, J.; Li, M.; Wan, X.; Jin, X.; Chen, S.; Yu, C.; Li, Y. Effect of miR-34a in regulating steatosis by targeting
PPARα expression in nonalcoholic fatty liver disease. Sci. Rep. 2015, 5, 13729. [CrossRef]
133. Wang, Y.; Zhu, K.; Yu, W.; Wang, H.; Liu, L.; Wu, Q.; Li, S.; Guo, J. MiR-181b regulates steatosis in nonalcoholic
fatty liver disease via targeting SIRT1. Biochem. Biophys. Res. Commun. 2017, 493, 227–232. [CrossRef]
[PubMed]
134. Dongiovanni, P.; Crudele, A.; Panera, N.; Romito, I.; Meroni, M.; De Stefanis, C.; Palma, A.; Comparcola, D.;
Fracanzani, A.L.; Miele, L.; et al. beta-Klotho gene variation is associated with liver damage in children with
NAFLD. J. Hepatol. 2020, 72, 411–419. [CrossRef] [PubMed]
135. Bala, S.; Marcos, M.; Kodys, K.; Csak, T.; Catalano, D.; Mandrekar, P.; Szabo, G. Up-regulation of microRNA-155
in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased
mRNA half-life in alcoholic liver disease. J. Biol. Chem. 2011, 286, 1436–1444. [CrossRef] [PubMed]
136. Csak, T.; Bala, S.; Lippai, D.; Kodys, K.; Catalano, D.; Iracheta-Vellve, A.; Szabo, G. MicroRNA-155 Deficiency
Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis.
PLoS ONE 2015, 10, e0129251. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 30 of 32
137. Bonci, D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat. Cardiovasc.
Drug Discov. 2010, 5, 156–161. [CrossRef]
138. Zhao, J.; Tang, N.; Wu, K.; Dai, W.; Ye, C.; Shi, J.; Zhang, J.; Ning, B.; Zeng, X.; Lin, Y. MiR-21 simultaneously
regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS ONE 2014, 9,
e108005. [CrossRef]
139. Tryndyak, V.P.; Marrone, A.K.; Latendresse, J.R.; Muskhelishvili, L.; Beland, F.A.; Pogribny, I.P. MicroRNA
changes, activation of progenitor cells and severity of liver injury in mice induced by choline and folate
deficiency. J. Nutr. Biochem. 2016, 28, 83–90. [CrossRef]
140. Tryndyak, V.P.; Latendresse, J.R.; Montgomery, B.; Ross, S.A.; Beland, F.A.; Rusyn, I.; Pogribny, I.P. Plasma
microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice
by a choline- and folate-deficient diet. Toxicol. Appl. Pharmacol. 2012, 262, 52–59. [CrossRef]
141. Hillman, E.T.; Lu, H.; Yao, T.; Nakatsu, C.H. Microbial Ecology along the Gastrointestinal Tract. Microbes
Environ. 2017, 32, 300–313. [CrossRef]
142. Martinez-Medina, M.; Denizot, J.; Dreux, N.; Robin, F.; Billard, E.; Bonnet, R.; Darfeuille-Michaud, A.;
Barnich, N. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier
function favouring AIEC colonisation. Gut 2014, 63, 116–124. [CrossRef] [PubMed]
143. Agus, A.; Denizot, J.; Thevenot, J.; Martinez-Medina, M.; Massier, S.; Sauvanet, P.; Bernalier-Donadille, A.;
Denis, S.; Hofman, P.; Bonnet, R.; et al. Western diet induces a shift in microbiota composition enhancing
susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci. Rep. 2016, 6, 19032.
[CrossRef] [PubMed]
144. Singh, R.K.; Chang, H.W.; Yan, D.; Lee, K.M.; Ucmak, D.; Wong, K.; Abrouk, M.; Farahnik, B.; Nakamura, M.;
Zhu, T.H.; et al. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med.
2017, 15, 73. [CrossRef] [PubMed]
145. Hills, R.D., Jr.; Pontefract, B.A.; Mishcon, H.R.; Black, C.A.; Sutton, S.C. Gut Microbiome: Profound
Implications for Diet and Disease. Nutrients 2019, 11, 1613. [CrossRef]
146. Brahe, L.K.; Astrup, A.; Larsen, L.H. Is butyrate the link between diet, intestinal microbiota and obesity-related
metabolic diseases? Obes. Rev. 2013, 14, 950–959. [CrossRef]
147. Lindstedt, G.; Lindstedt, S.; Gustafsson, B.E. Mucus in Intestinal Contents of Germfree Rats. J. Exp. Med.
1965, 121, 201–213. [CrossRef]
148. Wang, L.; Fouts, D.E.; Starkel, P.; Hartmann, P.; Chen, P.; Llorente, C.; DePew, J.; Moncera, K.; Ho, S.B.;
Brenner, D.A.; et al. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing
Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe 2016, 19, 227–239.
[CrossRef]
149. Hritz, I.; Mandrekar, P.; Velayudham, A.; Catalano, D.; Dolganiuc, A.; Kodys, K.; Kurt-Jones, E.; Szabo, G.
The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR
adapter MyD88. Hepatology 2008, 48, 1224–1231. [CrossRef]
150. Zhu, L.; Baker, S.S.; Gill, C.; Liu, W.; Alkhouri, R.; Baker, R.D.; Gill, S.R. Characterization of gut microbiomes
in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH.
Hepatology 2013, 57, 601–609. [CrossRef]
151. Wagnerberger, S.; Spruss, A.; Kanuri, G.; Volynets, V.; Stahl, C.; Bischoff, S.C.; Bergheim, I. Toll-like receptors
1-9 are elevated in livers with fructose-induced hepatic steatosis. Br. J. Nutr. 2012, 107, 1727–1738. [CrossRef]
152. Jin, R.; Willment, A.; Patel, S.S.; Sun, X.; Song, M.; Mannery, Y.O.; Kosters, A.; McClain, C.J.; Vos, M.B.
Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. Int. J. Hepatol. 2014, 2014, 560620.
[CrossRef] [PubMed]
153. Yoshimoto, S.; Loo, T.M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.;
Hattori, M.; et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence
secretome. Nature 2013, 499, 97–101. [CrossRef] [PubMed]
154. Devkota, S.; Wang, Y.; Musch, M.W.; Leone, V.; Fehlner-Peach, H.; Nadimpalli, A.; Antonopoulos, D.A.;
Jabri, B.; Chang, E.B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in
Il10-/- mice. Nature 2012, 487, 104–108. [CrossRef] [PubMed]
155. Zimmer, J.; Lange, B.; Frick, J.S.; Sauer, H.; Zimmermann, K.; Schwiertz, A.; Rusch, K.; Klosterhalfen, S.;
Enck, P. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur. J. Clin.
Nutr. 2012, 66, 53–60. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 2986 31 of 32
156. Aries, V.; Crowther, J.S.; Drasar, B.S.; Hill, M.J.; Williams, R.E. Bacteria and the aetiology of cancer of the
large bowel. Gut 1969, 10, 334–335. [CrossRef]
157. Conlon, M.A.; Bird, A.R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients
2014, 7, 17–44. [CrossRef]
158. Chassard, C.; Lacroix, C. Carbohydrates and the human gut microbiota. Curr. Opin. Clin. Nutr. Metab. Care
2013, 16, 453–460. [CrossRef] [PubMed]
159. Kim, H.J.; Bae, S.C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as
anti-cancer drugs. Am. J. Transl. Res. 2011, 3, 166–179.
160. Qin, Y.; Wade, P.A. Crosstalk between the microbiome and epigenome: Messages from bugs. J. Biochem. 2018,
163, 105–112. [CrossRef] [PubMed]
161. Krautkramer, K.A.; Kreznar, J.H.; Romano, K.A.; Vivas, E.I.; Barrett-Wilt, G.A.; Rabaglia, M.E.; Keller, M.P.;
Attie, A.D.; Rey, F.E.; Denu, J.M. Diet-Microbiota Interactions Mediate Global Epigenetic Programming in
Multiple Host Tissues. Mol. Cell 2016, 64, 982–992. [CrossRef]
162. Celis-Morales, C.; Livingstone, K.M.; Marsaux, C.F.M.; Macready, A.L.; Fallaize, R.; O’Donovan, C.B.;
Woolhead, C.; Forster, H.; Walsh, M.C.; Navas-Carretero, S.; et al. Effect of personalized nutrition on
health-related behaviour change: Evidence from the Food4Me European randomized controlled trial. Int. J.
Epidemiol. 2016, 46, 578–588. [CrossRef]
163. Ramos-Lopez, O.; Milagro, F.I.; Allayee, H.; Chmurzynska, A.; Choi, M.S.; Curi, R.; De Caterina, R.;
Ferguson, L.R.; Goni, L.; Kang, J.X.; et al. Guide for Current Nutrigenetic, Nutrigenomic, and Nutriepigenetic
Approaches for Precision Nutrition Involving the Prevention and Management of Chronic Diseases Associated
with Obesity. J. Nutr. Nutr. 2017, 10, 43–62. [CrossRef] [PubMed]
164. Arpon, A.; Riezu-Boj, J.I.; Milagro, F.I.; Marti, A.; Razquin, C.; Martinez-Gonzalez, M.A.; Corella, D.;
Estruch, R.; Casas, R.; Fito, M.; et al. Adherence to Mediterranean diet is associated with methylation changes
in inflammation-related genes in peripheral blood cells. J. Physiol. Biochem. 2016, 73, 445–455. [CrossRef]
[PubMed]
165. Yubero-Serrano, E.M.; Gonzalez-Guardia, L.; Rangel-Zuñiga, O.; Delgado-Casado, N.; Delgado-Lista, J.;
Perez-Martinez, P.; Garcia-Rios, A.; Caballero, J.; Marin, C.; Gutierrez-Mariscal, F.M.; et al. Postprandial
antioxidant gene expression is modified by Mediterranean diet supplemented with coenzyme Q(10) in
elderly men and women. Age 2013, 35, 159–170. [CrossRef] [PubMed]
166. Gutierrez-Mariscal, F.M.; Perez-Martinez, P.; Delgado-Lista, J.; Yubero-Serrano, E.M.; Camargo, A.;
Delgado-Casado, N.; Cruz-Teno, C.; Santos-Gonzalez, M.; Rodriguez-Cantalejo, F.; Castaño, J.P.; et al.
Mediterranean diet supplemented with coenzyme Q10 induces postprandial changes in p53 in response to
oxidative DNA damage in elderly subjects. Age 2012, 34, 389–403. [CrossRef] [PubMed]
167. Nicoletti, C.F.; Nonino, C.B.; de Oliveira, B.A.; Pinhel, M.A.; Mansego, M.L.; Milagro, F.I.; Zulet, M.A.;
Martinez, J.A. DNA Methylation and Hydroxymethylation Levels in Relation to Two Weight Loss Strategies:
Energy-Restricted Diet or Bariatric Surgery. Obes. Surg. 2016, 26, 603–611. [CrossRef]
168. Garcia-Caraballo, S.C.; Comhair, T.M.; Verheyen, F.; Gaemers, I.; Schaap, F.G.; Houten, S.M.; Hakvoort, T.B.M.;
Dejong, C.H.C.; Lamers, W.H.; Koehler, S.E. Prevention and reversal of hepatic steatosis with a high-protein
diet in mice. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2013, 1832, 685–695. [CrossRef]
169. Rahmanabadi, A.; Mahboob, S.; Amirkhizi, F.; Hosseinpour-Arjmand, S.; Ebrahimi-Mameghani, M. Oral
alpha-lipoic acid supplementation in patients with non-alcoholic fatty liver disease: Effects on adipokines
and liver histology features. Food Funct. 2019, 10, 4941–4952. [CrossRef]
170. Kapoor, S. Hepato-protective effects of alpha lipoic acid besides its role in preventing fatty liver disease. Liver
Int. 2013, 33, 162–163. [CrossRef]
171. Stoner, M.W.; Thapa, D.; Zhang, M.; Gibson, G.A.; Calderon, M.J.; St Croix, C.M.; Scott, I. α-Lipoic acid
promotes α-tubulin hyperacetylation and blocks the turnover of mitochondria through mitophagy. Biochem.
J. 2016, 473, 1821–1830. [CrossRef]
172. Rudkowska, I.; Caron-Dorval, D.; Verreault, M.; Couture, P.; Deshaies, Y.; Barbier, O.; Vohl, M.-C. PPARα
L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity. Mol. Nutr.
Food Res. 2010, 54, 543–550. [CrossRef] [PubMed]
173. Grenier, E.; Ziv, E.; Delvin, E.; Leduc, L.; Spahis, S.; Lafond, J.; Levy, E. n-3 fatty acids on utero programming
of insulin resistance, NASH and hyperlipidemia in Psammomys obesus. FASEB J. 2008, 22 (Suppl. 1), 687.5.
[CrossRef]
Int. J. Mol. Sci. 2020, 21, 2986 32 of 32
174. Boque, N.; de la Iglesia, R.; de la Garza, A.L.; Milagro, F.I.; Olivares, M.; Banuelos, O.; Soria, A.C.;
Rodriguez-Sanchez, S.; Martinez, J.A.; Campion, J. Prevention of diet-induced obesity by apple polyphenols
in Wistar rats through regulation of adipocyte gene expression and DNA methylation patterns. Mol. Nutr.
Food Res. 2013, 57, 1473–1478. [CrossRef] [PubMed]
175. Gracia, A.; Elcoroaristizabal, X.; Fernandez-Quintela, A.; Miranda, J.; Bediaga, N.G.; de Pancorbo, M.M.;
Rimando, A.M.; Portillo, M.P. Fatty acid synthase methylation levels in adipose tissue: Effects of an obesogenic
diet and phenol compounds. Genes Nutr. 2014, 9, 411. [CrossRef] [PubMed]
176. Morimoto, T.; Sunagawa, Y.; Kawamura, T.; Takaya, T.; Wada, H.; Nagasawa, A.; Komeda, M.; Fujita, M.;
Shimatsu, A.; Kita, T.; et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity
and prevents heart failure in rats. J. Clin. Investig. 2008, 118, 868–878. [CrossRef] [PubMed]
177. Wu, P.; Huang, R.; Xiong, Y.L.; Wu, C. Protective effects of curcumin against liver fibrosis through modulating
DNA methylation. Chin. J. Nat. Med. 2016, 14, 255–264. [CrossRef]
178. Rahmani, S.; Asgary, S.; Askari, G.; Keshvari, M.; Hatamipour, M.; Feizi, A.; Sahebkar, A. Treatment of
Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother. Res.
2016, 30, 1540–1548. [CrossRef]
179. Bruno, R.S.; Dugan, C.E.; Smyth, J.A.; DiNatale, D.A.; Koo, S.I. Green tea extract protects leptin-deficient,
spontaneously obese mice from hepatic steatosis and injury. J. Nutr. 2008, 138, 323–331. [CrossRef]
180. Park, H.J.; DiNatale, D.A.; Chung, M.Y.; Park, Y.K.; Lee, J.Y.; Koo, S.I.; O’Connor, M.; Manautou, J.E.;
Bruno, R.S. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing
hepatic antioxidant defenses in ob/ob mice. J. Nutr. Biochem. 2011, 22, 393–400. [CrossRef]
181. Bose, M.; Lambert, J.D.; Ju, J.; Reuhl, K.R.; Shapses, S.A.; Yang, C.S. The major green tea polyphenol,
(-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed
mice. J. Nutr. 2008, 138, 1677–1683. [CrossRef]
182. Ueno, T.; Torimura, T.; Nakamura, T.; Sivakumar, R.; Nakayama, H.; Otabe, S.; Yuan, X.; Yamada, K.;
Hashimoto, O.; Inoue, K.; et al. Epigallocatechin-3-gallate improves nonalcoholic steatohepatitis model mice
expressing nuclear sterol regulatory element binding protein-1c in adipose tissue. Int. J. Mol. Med. 2009, 24,
17–22. [CrossRef] [PubMed]
183. Kuzu, N.; Bahcecioglu, I.H.; Dagli, A.F.; Ozercan, I.H.; Ustundag, B.; Sahin, K. Epigallocatechin gallate
attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J. Gastroenterol. Hepatol. 2008,
23 (8 Pt 2), e465–e470. [CrossRef]
184. Nakamoto, K.; Takayama, F.; Mankura, M.; Hidaka, Y.; Egashira, T.; Ogino, T.; Kawasaki, H.; Mori, A.
Beneficial Effects of Fermented Green Tea Extract in a Rat Model of Non-alcoholic Steatohepatitis. J. Clin.
Biochem. Nutr. 2009, 44, 239–246. [CrossRef] [PubMed]
185. Chung, M.Y.; Park, H.J.; Manautou, J.E.; Koo, S.I.; Bruno, R.S. Green tea extract protects against
nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by
proinflammatory enzymes. J. Nutr. Biochem. 2012, 23, 361–367. [CrossRef] [PubMed]
186. Torres, L.F.; Cogliati, B.; Otton, R. Green Tea Prevents NAFLD by Modulation of miR-34a and miR-194
Expression in a High-Fat Diet Mouse Model. Oxidative Med. Cell. Longev. 2019, 2019, 4168380. [CrossRef]
[PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
